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ABSTRACT 
 
Cancer stem cells (CSCs), characterized by high levels of ATP-binding cassette, 
anti-apoptotic molecules, active DNA-repair and slow replication capacities, 
surviving to conventional anti-cancer therapies, able to eradicate only the highly 
proliferating tumor cells, represent the elective target for new therapies. 
Colorectal CSCs (CR-CSCs) represent a powerful tool for preclinical validation 
of target therapies. In particular the elucidation of the mechanisms that govern 
stem cell survival and differentiation appears very essential for the identification 
of new molecular targets in cancer therapy. Among the molecules that govern 
these processes there are the Bone Morphogenetic Proteins (BMPs), members of 
the TGF-b superfamily. Here we propose that a BMP7 variant (BMP7v) have an 
important antitumoral and anti angiogenetic effect on CR-CSCs inducing a 
differentiation program and making these cells more sensitive to conventional 
chemotherapy drugs. BMP7v in vitro administration, activates the BMP signaling 
pathway in CR-CSCs, reducing the percentage of stem cell marker expression and 
enhancing epithelial colonic differentiation marker expression. BMP7v reduces 
self-renewal of CR-CSCs inducing their exit from quiescence and, reducing their 
typical mesenchymal trait, decreases their invasive and endothelial cord formation 
capacity. In vivo, BMP7v decreases tumor growth and stem cell marker 
expression, enhancing differentiation compared with control mice and in 
combination with CRC standard chemotherapy reduces tumor growth, inducing a 
differentiative and antiproliferative effect, associated with a strong anti-
angiogenic role. In addition, BMP7v as second-line of treatment also showed a  
significant anti-tumor activity in xenografts refractory to chemotherapy. Our data 
support the use of BMP7v as differentiative agent in combination with cytotoxic 
drugs for the treatment of CRC, and the use of BMP7v provides a potentially 
powerful and novel approach for the treatment of tumor disease. 
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INTRODUCTION 
 
Colorectal cancer and stem cell theory 
The colorectal cancer (CRC) is one of the most common cancers in Western 
countries. It represent the third form of cancer for frequency and the second 
leading cause of cancer death due to the resistance to current clinical therapies in 
the world. (1). 
Nowadays, the most important approaches, for the managment of this complex 
pathology remain the prevention and the early diagnosis, although a large 
numbers of patients after surgery and adjuvant therapy still develop recurrences 
and metastasis, due to the acquisition of resistance to conventional therapy, such 
as chemo- and radio-therapy (2). 
The colorectal cancer represent a classic example of a multistep pathogenesis, 
characterized by the acquisition of aberrant function of a proto-oncogene or loss 
of function of a tumor suppressor gene (3). Many studies showed that at least 4–5 
mutations are necessary to generate an invasive carcinoma (4). Some of these 
mutations seem to follow a constant trend, within the same sequences, and they 
are shared by many patients affected by colon-rectal cancer, unlike, other different 
mutations are individuals and therefore necessary to determine the final phenotype 
of disease (5). Many evidences on colon cancer mutations derived from studies on 
hereditary forms, representing 5% to 10% of all colon cancer cases. In particular, 
Familial adenomatous polyposis (FAP) is an autosomal dominant CRC syndrome 
caused by a mutation in the APC (adenomatous polyposis coli) gene which 
characterizes multiple CRC (6-8). 
In 1990, Fearon and Volgestein proposed a genetic model of colorectal 
carcinogenesis based on the accumulation of genetic mutations that occur in 
sequence, defining a particular staging of tumor development (9).  
The main event which characterizes the onset of CRC is represented by 
mutations-inactivating the gene APC that lead to hyperproliferation of the normal 
intestinal epithelium with the formation of adenomas class I (early adenoma ). In 
fact, the APC mutations are reported as the initiating gatekeeper that regulate 
positively the Wnt pathway in patients with FAP (10). The key role of APC 
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protein is represented by the modulation the cytoplasmic levels of beta-catenin, a 
protein that migrating into the nucleus activates the transcription of genes 
involved in the regulation of proliferation, differentiation, migration and apoptosis 
(11).  
The progression from early adenoma towards the stage of intermediate adenoma 
is related to the acquisition of B-RAF and K-RAS mutations. These mutations, 
mutually exclusive, determine the constitutive activation of the Ras-Raf-MAPK 
protein signaling pathway.  
The loss of heterozygosis involving the chromosome 18q, the mutations in 
SMAD4 (Small Mother against DPP homolog 4), CDC4 (Cell Division Cycle 4) 
and DCC (Delected in Colorectal Cancer) or alternatively mismatch repair 
deficiency, P53, Bax and IGFR2 (insulin-like growth factor receptor 2) are 
involved in the transition to advanced adenoma (adenoma late) (4, 12, 13). 
Finally, a key event in the transition from advanced adenoma to carcinoma is 
represented by acquisition of mutations in one of the most important tumor 
suppressor genes, TP53. It is a powerful transcription factor, able to maintain the 
integrity of the genome through the regulation of the expression of more than 300 
genes involved in various cellular processes such as apoptosis, cell cycle arrest, 
senescence and DNA repair.  
The tumor suppressor gene TP53 is mutated in about 95 % of human cancers of 
various origins. Cancer cells that are non-functional TP53 have a substantial 
advantage in growth, since they can proliferate actively, even under conditions of 
stress or damage to the genome, developing resistance to apoptosis.  
Finally, the accumulation of additional mutations, many of which are still not 
known, induce the transformation in metastatic carcinoma (14). Fig.1. 
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Fig.1. Schematic representation of colorectal cancer multistep progression. (Di Franco S. et 
al., Encyclopedia of Molecular Cell Biology and Molecular Medicine, Wiley.) 
 
In the last decades the tumor biology has revolutionized the old view of 
tumourigenesis. CRC, as the other tumors, have long been consider as an 
exclusively genetic disorder. Nowadays, several studies showed that tumors are 
constitute by a highly heterogeneous population of tumor cells which differ in 
morphology, marker expression, proliferation capacity and tumorigenicity. To 
better describe the role of the different malignant cells within the same tumor, and 
to explain this morphological, proliferative and functional heterogeneity, two 
models have been proposed: the stochastic and hierarchical models. 
The first model, described by Nowell in 1976 (15) proposed that all cells within a 
tumor are biologically homogenous and able to regenerate the tumor (16). This 
model of tumorigenesis, in fact, describes the tumor formation as a process 
multistep due to the sequential accumulation of mutations in oncogenes and tumor 
suppressor genes. Accordingly, all cells within the same tumor are able to initiate 
a new tumors, but this theory does not consider the high cellular heterogeneity, 
the chemoresistance, the minimal residual disease and the tumor recurrence. In 
sum, tumors consist of a heterogeneous cell population that, acquiring new 
mutations, undergoes uncontrolled proliferation and invasivity. 
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Otherwise, the hierarchical model, considering all the factors intrinsic and 
extrinsic involved in defining cell behavior, such as, genomic instability, levels of 
transcription factors, signalling pathways, microenvironment and immune 
response, is based on the analysis of the high cell heterogeneity within the tumor 
in terms of features, surface markers expression, proliferation kinetics and tumor 
initiation capacity (17). 
This model suggest that only a subset of tumor cells within the tumor mass, called 
Cancer Initiating Cells or Cancer Stem Cells (CSCs), can initiate and sustain 
tumor growth (18). These cells possess the tumorigenic and self-renewal capacity, 
and the ability to differentiate in non-self renewing cells, that acquiring 
proliferative capacity, constitute the tumor bulk (19). Fig.2. 
 
 
 
 
 
 
 
Fig.2. Two general models of heterogeneity in solid cancer cells: a) stochastic and b) 
hierarchical models. (Reya T. et al. Stem cells, cancer, and cancer stem cells, Nature 2001) 
 
In the last years, novel insights in cancer research have suggested that the capacity 
to initiate and sustain tumor growth is a unique characteristic of this small subset 
of cancer cells with stemness properties within the tumor mass, called “cancer 
stem cells” (CSCs) or “tumor-initiating cells”, that have the capacity to propagate 
the tumor upon transplantation into immuno-compromised mice (19). 
CSCs are defined by their stem cell-like features that share with the normal stem 
cells that are characterized by self-renewal and pluripotent differentiation 
capacity. These cells are responsible to generate, through several cycles of 
division, progenitor cells which give rise to non-tumorigenic differentiated 
population that represent most part of the tumour mass. CSCs could derive either 
from self-renewing normal stem cells (SCs) that acquire epigenetic and genetic 
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changes required for tumorigenicity or from proliferative progenitor cells (PCs) 
that reprogramming themself acquire the self-renewal potential capacity (20). 
Emerging evidences suggest that CSCs isolated from a variety of tumors types 
retaining the tumorigenic capacity are responsible for the propagation, relapse and 
metastatic dissemination. CSCs can explain the phenomenon of the tumour 
chemoresistance in which several mutations confer to these cells drug-resistance, 
altered cell cycle checkpoints and impaired apoptosis machinery. For all these 
reasons, CSCs survive to conventional treatments giving often rise to minimal 
residual disease (MRD). Therefore to better understand the mechanisms that 
maintains stemness features and the subsequent characterization of CSCs could be 
crucial to develop new most appropriate anti tumor strategy approaches. 
Common signaling pathways, including Wnt, Notch and Sonic Hedgehog are 
involved in the regulation of normal and cancer stem cell. Many evidences 
underlining the importance of these cellular signalling showed as their 
deregulation plays an key role in the tumor development (21). Accordingly, 
several studies suggest the importance of self renewal pathways activation for 
CSCs maintainance (22). 
The CSCs theory has changed the conventional therapeutic approches, suggesting 
an alternative strategy targeted to these cellular subset. The CSCs are 
characterized by high resistance to conventional chemotherapeutic drugs that kill 
the rapidly proliferating cells sparing the slow dividing cells, through a particular 
upregulation of ATP-binding cassette transporters, active DNA-repair capaciy and 
overespression of antiapoptotic molecules (23, 24).  
Dick and collegues were the first to isolate and characterize CSCs from acute 
myeloid leukemia (AML) in blood and bone marrow. In particular they isolated a 
sub-population of CD34+CD38- from patients affected by AML, and they 
demonstrated that only this cellular subset was able to form colonies in vitro 
experiments. They also analized that only this subset was able to reproduce the 
parental tumor phenotype, when inoculated into immunodeficient mice (25, 26). 
Using a similar procedure many research groups identified a large number of 
tumor stem cell from a different solid tumor type. In particular, the first CSCs 
obtained from a solid tumor were a cellular subset CD44+CD24- isolated from 
breast cancer by Al Hajj et coll. (16). Subsequently, were isolate several different 
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CSCs tumoral type: brain (27), colon (28-30), head and neck (31), pancreas (32, 
33), melanoma (34), mesenchymal (35), hepatic (36), lung (37), prostate (38), and 
ovarian (39) tumors. 
 
Colon crypts and stem cells 
Although the SCs and CSCs characterization has been long studied, several 
molecules have been identified as a putative stemness markers, up to now, none of 
the markers studied seems to be exhaustive. Scientific evidences underline the 
importance to use different combinations of these markers in order to obtain a cell 
population enriched in stem cells. 
The adult intestinal epithelium presents a particular structure ordered into crypts 
and villi, organized with a hierarchical organization, composed by three different 
cell types: the colonocytes or columnar cell, the mucin-secreting goblet cells and 
the endocrine cells, originated from a colonic stem cell. These stem cell, located at 
the base of the crypt are surrounded by mesenchymal cells that form the stem 
niche, in which the stem cell, displaying stemness features, can generate through 
asymmetric division, a cell identical to itself , and a transit cell. The transit cell 
(rapidly dividing cells) proliferating and differentiating, migrates along the crypt, 
representing all the intestinal lineage (40-45). According to this theory these stem 
cells are responsible for the high turn over rate of the colonic epithelial cells (46-
48). 
This particular and complex structure of the colon crypts has made particular 
difficult the studies about the mechanisms of crypt formation from a single stem 
cell. The first study regarding the stem cell position in the colon was conducted by 
Chang et al. using 3H-thymidine injection, and recently it was confirmed using 
bromodeoxyuridine DNA-labeling dye (49, 50). 
Two different models have been proposed regarding the positioning of the stem 
cells: the “stem cell zone” model and the “ +4 position” model. According to the 
first model, the colon stem cell reside at the very bottom of the crypts. Unlike, the 
second model describes that the stem cells are located at the +4 position above the 
Paneth cells at the base of the crypts (51). 
Although the absence of a specific colonic stem cell markers makes their 
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identification and positioning very difficult, the colonic stem cell can be 
characterized by two main features: self-renewal and differentiation capacity. 
Stem cells may undergo asymmetric division, but they can also generate two 
identical stem cells via symmetric division that acquiring a diffentiated phenotype 
regenerate the colon tissue. Then, in the first case, it is possible to obtain a lineage 
expansion, but in the other case, a lineage extinction, because the differentiated 
progeny undergo to senescence. 
Accordingly with the CSCs theory it is widely accepted that the stem cells are 
responsible for the origine of the cancer. Their slow division cycle, allow them to 
accumulate several mutations over time up to define them CSCs (52-54).  
Different molecules have been proposed as a stemness markers: Musashi 1(Msi1), 
EphB receptors, Bmi 1, Lgr5. 
Msi1, an RNA binding protein, widely studied in Drosophila Melanogaster, seems 
to be involved in the asymmetric division that regulate the neural development, 
also in mammals. In human and murine small intestine it is located at the base of 
the crypts. Its silencing determines tumor growth arrest by Notch inhibition and 
p21 upregulation, proteins involved in stemness mainteinance (55-57).  
EphB2 receptor is tyrosine kinase receptor, belonging to the family of Wnt target 
gene, it is expressed in a decresing gradient from the crypt base toward the 
differentiated cell compartment (58). This expression along the crypts seems 
regulate the migration and proliferation of intestinal epithelium; mutants in their 
ligands, or mutant forms of these receptors involve in intestinal 
compartimentalization defects. Underlining their important role in the intestinal 
positioning of the different cell types along the crypts. (59). 
Bmi1, a repressor of Polycomb group, is involved in hematopoietic, breast and 
neural self renewal. In the small intestine it is expressed near to the bottom of the 
crypts (60, 61). 
Lgr5 is a G protein coupled receptor, belonging to the family of Wnt target gene. 
Its expression in a single cells is able to regenerate a crypt-like structure in vitro 
constituted by all cell type of colonic epithelium (62). This and other markers as 
have been associated with CSCs phenotype. 
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CR-CSCs identification, isolation and expansion 
The existence of colorectal CSCs (CR-CSCs), have been showed, for the first 
time, thanks to the detection of a new stemness markers, the transmembrane 
glycoprotein, CD133. This surface expressed polypeptide is associated with self 
renewal and tumor initiating cells, this protein was first associated as a marker for 
hematopoietic stem cells and progenitor cells, and successively used in other 
tumor type: (63): brain (27), prostate, hepatocellular and colon tumors (28-30, 64, 
65). 
Recently two indipendent groups have revealed that only CD133+ subset of tumor 
cells within a colon carcinoma, is able to initiate a tumor outgrowth (28-30). 
Accordingly, it has been showed that a small group of CD133+ cells is able to 
serially reproduce the original human tumor phenotype, rather than an high 
number of CD133- cells that fail to generate xenograft tumors in immuno-
compromised mice. In line with these data, only the tumorigenic CD133+ cells 
population generated crypt-like structures in vitro under differentiation condition 
on matrigel (65). In addiction, these cells during differentiation in vitro and in 
vivo acquire a typical epithelial colonic marker, CK20, reducing at the same time 
the CD133 stem cell marker.  
Accordingly, many clinical reports suggest CD133 as an indipendent prognostic 
marker and its combination with a nuclear localization of beta catenin is 
associated with a reduced patients survival (66-69).  
In sum, several research groups demonstrated that only the CD133+ cellular sub-
population, within a colon carcinoma, is able to initiate and sustain tumor growth 
(68-70).  
Moreover, mantaining the CD133+ cells with the same conditions of 
neurospheres, these cells were expansed for long term without loss their ability to 
reproduce human original tumor phenotype, underlining the self renewal and 
tumor initiation capacity of these sub population (28, 29).  
O’Brien and collegues, in order to evaluate whether all the CD133+ cells are CSCs 
or whether these subpopulation contains also more differentiated progenitors, 
through serial dilution assays, showed that the CD133+ subpopulation not only 
contains cancer initiating cells.  
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Accordingly, recent studies analyzed a new sub-group, contained in CD133+ cells, 
the CD44+/Epcam High/CD166+ stem like cells. Dalerba et al., (30) demonstrated 
that the CD44+/Epcam high cell subpopulation injected in NOD-SCID mice, is 
able to reproduce a tumor xenograft phenotypically similar to parental one.  
In a similar way, Du’s et al., (70) showed that also CD44 could be considered a 
putative marker, able to discriminate a subpopulation capable to growth in vitro as 
spheres and in vivo producing xenografts, resembling the parental human tumor. 
The role of CD133 as a marker of stem cell has long been debated, in particular, 
after the Shmelkov et al. publication, in which it was shown that CD133 is 
expressed ubiquitously in both undifferentiated and mature colonic cells (71). 
While the lack of CD133 expression is only found in the stromal and 
inflammatory cell compartment.  
Differently, Zhu et al. analizing the role of Prominin1, the mouse analogue of 
CD133, in adult colon tissue, showed that the Prominin1+ cells marking the adult 
colon stem cells, represent the target of tumoral trasformation. (72). 
On the bases of these conflicting data, it became clear that the use of a single 
marker is not adequate for a correct CSCs identification and isolation, to identify 
the subpopulation of CSCs, it would be more appropriate to use a panel of 
markers and to standardize protocols that can validate the use of a new marker. 
For all these reasons, several surface molecules have been proposed to mark colon 
CSCs, such as CD133, LGR5, CD44 and CD166. (73, 28-30).  
Recently, it has been demostrated that undifferentiated tumorigenic CRC cells 
could be expanded as tumor spheres in vitro using a serum-free medium 
containing EGF and basic FGF (74). The tumor spheres, infact, contain an 
heterogeneous cell population expressing a variable percentage of CD133, 
CD166, CD44, CD29, CD24 and nuclear beta-catenin. More recently ALDH1, a 
detoxifying enzyme, has been proposed as a specific marker able to identify, 
isolate and track human normal and CSCs during CRC development (75, 76). 
This marker is expressed by the CD44+ or CD133+ cells, located at the base of 
normal crypts. After sorting the ALDH1 high cells, injected subcutaneously in 
NOD SCID mice, generate tumor xenografts (76).  
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The isolation of CSCs is based essentially on two different approaches: the use of 
a culture medium serum-free that maintain stemness-selective conditions, 
originally developed for neural stem cell culture (77) or the direct selection by 
magnetic sorting or FACS technology for putative markers distinctively expressed 
by a cell subpopulation. On the bases of these procedures there is a common step 
in which the surgical excisions of solid tumours are processed by mechanical 
and/or enzymatic digestion to obtain a single-cell suspension. This freshly digest 
obtained is constitute by an cells heterogeneous mixture of the original tissue. In 
order to selectively obtain CSCs, the digest is cultured into ultra-low-adhesion 
flasks in a specific serum free medium, supplemented with growth factors such as 
basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). These 
conditions allow the undifferentiated tumour cells, stem and transit amplifying 
cells, to survive and slowly proliferate, while the differentiated cells die through 
anoikis. Sphere-forming cells are maintained in culture by dissociation and re-
plating as single cells, and retain the tumorigenic potential when injected into 
immunocompromised mice, reproducing the same morphological and antigenic 
features of the original tumour, data showed by histological examination of 
xenografts generated from spheres. This tumorigenic capacity is serially 
maintained, and the xenografts can be digested and the cells obtained can be 
indefinitely propagate under stemness conditions, maintaining the stem like 
features as well as the capacity to reform tumors. As previously described, a 
single clonogenic CD133+ cell, contained in CRC spheres is able to reproduce the 
original tumor, including the CSC compartment and the differentiated progeny. 
Alternatively, the second procedure, involves the selection of putative stem cell 
marker from the whole digest, by the use of monoclonal antibody directly or 
indirectly conjugated with magnetic beads. This sorting allow a double positive 
and negative selection, separating labelled and unlabelled cells, but this procedure 
permit only a single-marker selection. Another alternative method is represented 
by FACS sorting, which allows sorting of different populations with multi 
parameter analysis, testing contemporary several antibodies conjugated to 
different fluorochromes. 
Moreover the sorted cells can be also cultivated in stem cell conditions and also 
injected into immunocompromised mice to directly test the tumorigenic capacity 
(74).  
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Intestinal Niche 
Fibroblast, endothelium, inflammatory cells, cytokines and growth factors 
secreted by these cells, constitute the intestinal niche and are involved in CSCs 
maintenance at the base of colon crypts. They finely regulate the balance between 
self-renewal and differentiation (78-80). Indeed the pluripotency of colon SCs is 
strongly controlled by microenvironment that plays a crucial role ensuring a fine 
equilibrium between important pathways, such as PTEN-PI3K-Akt (81, 82), Bone 
Morphogenetic Protein (BMP) (83), Notch (84) and Sonic hedgehog (Shh) (85). 
In particular the intestinal sub-epithelial myofibroblast (ISEMFs) surrounding the 
normal colon stem cells, regulate this balance secreting hepatocyte growth factor 
(HGF) for maintenance of stem cell in the intestinal niche. The presence of 
ISEMFs or HGF, as demonstrated by Vermulen et al., restore the stem cell 
phenotype, inducing a cellular de-differentiation (80). 
The colon crypt unit represented in figure 3, shows a particular cellular 
distribution in which at the basis of the crypt are located the mesenchymal cells 
(ISEMFs) and their secreted factors responsible for the stem cell niche 
maintenance, while along the villux apex, where are located several Wnt 
inhibitors, in order to reduce the stemness features it is possible to identify a 
progressive cellular differentiation. The pathways mentioned above, are involved 
in self renewal and are de-regulated both in normal and CSCs (21, 22).  
One of the most studied pathway envolved in CSCs progression is represented by 
the Wnt signalling. 
The Wnt signalling in the basis of the crypts promotes nuclear beta catenin 
accumulation, which activate the transcription of several genes involved in cell 
cycle regulation and proliferation. Beta catenin also induces the expression of 
EphB1-2, which regulate stemness, cell migration and differentiation (86-88). 
The distribution of Wnt pathway members, results particularly regulated. Wnt 
ligands are predominantly expressed at the basis of the crypts and are reduced 
along the crypt where more differentiated cells reside, and where are most express 
the Wnt inhibitors factors (88-90). 
In addiction to Wnt pathway, BMP, Notch and Shh pathways regulate the niche 
homeostasis. 
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BMP proteins are TGF-beta superfamily members that through binding to 
receptors BMPR1A, BMPR1B and BMPR2 can trigger different biological 
processes in CSCs (91). 
The activation of this pathway promotes the phosphorylation of Smad1, 5 and 8 
that in association with SMAD 4 translocate into the nucleus and in cooperation 
with other transcriptor factors regulate the target genes expression (92, 93). 
Recent data have demonstrated that the BMPs promote terminal differentiation 
and apoptosis (94). Kosinsky et al., analyzed the distribution of the different 
factors along the crypt: the cells at the apex of the crypt express high levels of 
BMPs, while at the basis of the crypt, their levels are reduced, but the levels of 
BMPs antagonist, produced by myofibroblasts, contribute to the maintenance of 
stemness (95, 83). 
Notch pathway is envolved in intestinal SCs fate and includes four different trans-
membrane receptors (Notch1 to Notch4). The binding of five different ligands 
(Jagged-1, -2, Delta-like 1, 2 and 4) induces the release of the Notch intracellular 
domain that translocates into the nucleus where it forms a complex with DNA-
binding proteins activating the target genes transcription involved in epithelial cell 
fate determination (96). Recent reports showed its key role in intestinal 
homeostasis and neoplastic transformation. Moreover, the expression of Notch 
intracellular domain blocks cell differentiation, inducing expansion of immature 
progenitors (97, 84). Defects in Notch pathway were observed in colon cancer 
stem cells (CCSCs), using an antibody anti DLL4 (an important Notch pathway’s 
component) to directly inhibit human colon cancer xenograft growth.  
Finally, Sonic Hedgehog pathway regulate the gut organogenesis, binding to its 
receptor Patched (PTCH), allowing the release of a G-coupled protein 
Smoothened (Smo), which with the GLI transcriptors factors migrate into the 
nucleus inducing target gene activation (85) 
In several cancers, such as leukemia, pancreas, stomach, prostate, breast, 
glioblastoma and colon cancer were found many alterations in the Hedgehog 
pathway (98-103). 
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In conclusion, the aberrant alteration of these pathways involved in self-renewal 
of the intestinal stem cells could be the driving force that promote colon cancer. 
(104)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. Graphic representation of a colon crypt. (Di Franco S. et al. Colon Cancer Stem Cells: 
Bench-to-Bedside-New Therapeutical Approaches in Clinical Oncology for Disease Breakdown. 
Cancers 2011).  
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Clinical implication of CR-CSCs and BMPs as alternative therapeutic 
strategy  
The CSCs theory, in colorectal cancer, has exciting clinical implications, 
confirming that the therapy failure and relapses are due to the CSCs resistance. 
Indeed, CSCs, retaining the stemness features, such as quiescence, self-renewal 
ability and multidrug resistance, represent the population intrinsically 
refractoriness to conventional therapies developed to eradicate the rapidly 
dividing cells that constitute the majority of the non stem cell component within 
the tumor.  
Nowadays, patients with metastatic CRC are treated with two useful protocols 
FOLFOX (Folinic acid/Fluorouracil and Oxaliplatin) and FOLFIRI (FOLFOX 
plus vitamin B and irinotecan). Neoadjuvant chemotherapy for these patients, is 
represented by anti-angiogenic drugs as the Bevacizumab, a humanized 
monoclonal antibody that targets the vascular endothelial growth factor (VEGF), 
which plays an inportant role as angiogenic factor in primary and metastatic 
human CRC (105, 106). Another neo-adjuvant drug is Cetuximab, also known as 
Erbitux, a monoclonal antibody that inhibits the epidermal growth factor receptor 
(EGFR), indicated for the treatment of EGFR expressing patients affected by 
KRAS wild-type metastatic colorectal cancer, alone or in combination with 
FOLFIRI (107). 
The future of diagnostics and treatments of tumor disease should aim to eliminate, 
not only the terminally differentiated component of the tumor bulk, but, it should 
be focused, in particular, to the subpopulation of cancer stem cells that represent 
the driving force for the tumor expansion (19). In order to evaluate the CR-CSCs 
role in the therapy response, recurrence and metastasis, a recent work showed that 
the subpopulation of CD133+ CR-CSCs results more resistant to both 
conventional chemotherapeutic drugs, and innovative therapies, compared to 
epithelial cells that constitute the majority cell population within the tumor (65, 
74). 
These recent findings support the idea that tumor-initiating cells are highly 
resistant to cytotoxic cancer therapies, underlining the importance of their role in 
colorectal tumors refractoriness and recurrence also many years after the 
"successful" treatment of primary tumour.  
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The CSCs contribute to the poor therapeutic sensitivity through many 
mechanisms, such as preferential activation of DNA damage checkpoint, high 
levels expression of ABC transporters and anti-apoptotic molecules, slow 
replication capacity and other aberrant molecular mechanisms that destroy the 
normal balance between proliferation and survival or cell death (23). 
In addition the CSCs refractoriness is finely regulated by microenvironmental 
soluble molecules that are involved in many different sectors of tumor 
development, regulating the growth, migration, and differentiation of all cellular 
components into both the tumor mass and in the microenvironment. 
The possibility to isolate and study CSCs represents a revolutionary approach in 
cancer research and these cells represent the elective target for new therapies, 
endowed to high and selective toxicity towards the specific tumor with reduced 
toxicity for normal cells. 
An alternative therapeutic strategy seems to be represented by selectively target of 
CSCs pathways . 
Recent reports have demonstrated that the autocrine production of IL-4 by cancer 
cells from breast, thyroid, colon, and lung acts as negative regulator of apoptosis, 
conferring resistance to death receptors and chemotherapy-induced cell death 
(108). Moreover IL-4 seem to be involved in stimulation of activated B-cell, in T-
cell proliferation and the differentiation of CD4+ T-cells into Th2 cells (109). The 
use of anti–IL-4 neutralizing antibody or IL-4 receptor α antagonist, on CR-CSCs, 
inhibiting IL-4 signaling transduction pathway, sensitizes these cells to 
chemotherapeutic agents through down-regulation of anti-apoptotic proteins, such 
as cFLIP, Bcl-xL, and PED. Moreover, the combined use of IL-4 antibodies plus 
5-fluorouracil or oxaliplatin also reduces xenografts tumor growth (65). 
Concluding, recent studies have evaluated that the CR-CSCs CD133+, are 
protected by apoptosis phenomenon through the up-regulation of IL-4 (110). 
Another important approach could be represented by cancer immunotherapy. 
Although the cancer cells are less immunogenic than their normal counterpart, the 
immune system could plays a crucial role in order to effectively and safely 
increase antitumor responses recognizing and eliminating them (111). Although, 
these cells do not express MHC molecules, making tumor cells resistant to αβ T 
cell-mediated cytotoxicity, recently, it has been demonstrated that a subpopulation 
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of T cells, the γδ T cells, show potent MHC-unrestricted lytic activity versus 
different tumor cells in vitro, suggesting their potential employment in anticancer 
therapy. γδ T cells have been isolated and identified from tumor infiltrating 
lymphocytes in different cancer types. 
The development of targeted therapies for colorectal cancer requires new 
therapeutic regiments that aims to eliminate the self-renewal compartment of 
tumor mass by targeting stemness features owned by CR-CSCs, making this 
population more sensitive to conventional drugs. This is the main goal that the 
differentiation therapy aims to achieve. 
The therapy based on the induction of differentiation is aimed to affects the self 
renewal ability of CSCs, and could represent an alternative way to inhibit tumour 
growth. 
Among the molecules that govern stem cell survival and differentiation, the Bone 
Morphogenetic Proteins (BMPs), a subgroup of TGF-b superfamily members, 
play an important role in the regulation of colon stem cell features and contribute 
to the network of the signals that define the intestinal stem cell niche modulating 
the equilibrium between proliferation and differentiation signalling pathways 
(112-114)  
These proteins and their intracellular signaling components have been conserved 
in Drosophila and Caenorhabditis elegans and they were originally isolated from 
bone. The major contribution to their isolation and characterization was made by 
Sampath and Reddi (115). 
BMPs are synthesized as large precursor proteins in the cytoplasm where they are 
proteolytically processed in a mature proteins (116). The mature BMP molecules 
are characterized by a cysteine knot with the seven conserved cysteine domains. 
The dimeric form is active as a homodimer or heterodimer with a molecular 
weight of about 30-38 kDa. 
BMPs bind to two different transmembrane serine/threonine kinase receptors, 
type I (BMPRI) and type II (BMPRII). Type I receptors include activin receptor 
type IA (ActRIA or ALK2) and BMP receptors type IA and IB (BMPRIA or 
ALK3; BMPRIB or ALK6), while type II receptors are represent by BMP 
receptor type II (BMPRII), activin receptor type IIA and IIB (ActRIIA and 
ActRIIB) (117, 118). After the formation of heteromeric complexes, type II 
 19 
receptor phosphorylates the type I receptor (119) and the signalling pathway is 
then activated through Smad and non-Smad mechanism (117, 119). In addition to 
the Smad pathway, indeed, the BMPs activate an alternative pathway, which 
includes p38 and ERK MAP kinases (120). When Smad 1,5,8 protein (R-Smad) 
are phyosphorylated by the type I receptors, they can interact with co-Smad 
(Smad4) and after translocate into the nucleus in order to initiate the transcription 
of BMPs response genes (121). 
The Inhibitory Smads, Smad 6/7, inhibits BMP signaling (122), indeed, BMPs 
activation is tightly regulated by the presence or the absence of antagonists and 
inhibitors such as Gremlin, Chordin and Noggin (83). BMP antagonists are 
soluble factors that control BMPs signaling with various degrees of affinity and 
specifity, binding the BMPs, preventing the functional receptor/ligand interaction: 
twisted gastrulation (TSG), chordin and noggin and the DAN-family of inhibitors. 
BMPs are involved in the earliest stage of development, and play a key role in the 
normal intestinal development, growth and morphogenesis. Their signalling act to 
mediator between epithelial and mesenchymal stroma interaction necessary for 
the correct intestinal homeostasis (123).  
During the human and mouse intestine development, BMP7 and BMP6 were 
found, respectively, on the intestinal epithelium and smooth muscle cells (124, 
125). Moreover, the high expression of BMP2 and BMP4 in the mesenchymal site 
drive the villus formation (126). In particular many reports showed that the BMPs 
pathway is functional in all three tissue layers of the gastro-intestinal tract, to 
allow the reciprocal correct interaction. Mice overexpressing the BMP-antagonist 
noggin, undergo to abnormal villus morphogenesis, associated with stromal and 
epithelial hyperplasia, ectopic crypt formation, due to low levels of BMPRIA and 
pSmad1/5/8 (123).  
All these results suggest that human gastro-intestinal and chronic intestinal 
diseases, could be associated with defects in the BMPs signaling pathway (113).  
Hardwick et al., have demonstrated that the mature colonocytes at the epithelial 
surface of normal human and mouse colon, express BMP2, the BMP receptors (Ia, 
Ib, II), phosphorylated Smad1 and Smad4 (112). Stroma and crypt epithelium of 
the adult mouse intestine show an high expression of BMPRIA and BMP2 (123, 
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127). While, Haramis et al showed that BMP4 is expressed in stromal cells and 
mesenchimal cells surrounding the crypt and glands of the intestine (127, 113). 
The BMPs pathway components result highly expressed in colon tops while the 
BMP antagonists gremlin 1, gremlin 2 and chordin-like 1, produced by 
myofibroblasts and smooth muscle cells, are located in basal colon crypts.  
Juvenile polyposis (JP), is an autosomal dominant hamartomatous polyposis 
syndrome in which germline mutations of two members of the BMPs pathway are 
involved. The patients, having mutations or deletions in SMAD4 and BMPR1A 
genes (128-130) are predisposed to upper gastrointestinal and colorectal cancer, in 
almost half of the cases. JP patients, with SMAD4 mutations, showed a significant 
prevalence of gastric polyposis (131). SMAD4, known as a tumor suppressor gene 
in pancreatic and colon cancer, in JP acts as a susceptibility gene, a “gatekeeper“, 
its loss of function results in polyp formation in which an important role is played 
by stromal inflammatory response regulating epithelial tumorigenesis (132). 
Homozygous SMAD4 knockout mice, develop polyps, with thickened intestinal 
mucosa and loss of villus architecture showing plasma cell infiltrates into the 
stroma, while mice with conditional SMAD4 deletion in the intestinal epithelial 
cells did not develop intestinal tumors (133). Although, JP patients with a 
germline SMAD4 mutation, showed biallelic inactivation of SMAD4 in both the 
epithelium and stroma, suggesting a common clonal origin (134). 
Another gastro-intestinal disease, Familial adenomatous polyposis (FAP), is an 
autosomal dominant syndrome, characterized by hundreads of adenomatous 
colorectal polyps due to a deletion in the adenomatous polyposis coli (APC) gene, 
localized on chromosome 5q21. APC gene, as above mentioned, is involved in 
ubiquitine-mediated degradation of beta catenin, regulating Wnt signalling and its 
functional defects leads to uncontrolled cell proliferation (135). In FAP patients, 
an higher expression of Wnt signaling molecules, results in BMPs signaling 
downregulation, differently, in intestinal homeostasis, the BMPs inhibit the 
effects of Wnt-pathway to regulate the intestinal stem cell proliferation and 
repression of polyps formation (113, 127). Many results showed that 
heterozygous APC mutant mice, with higher expression of the BMPs antagonist 
Gremlin 1 and lower BMP2 and BMP4 expression develop severe polyposis and 
faster rate of tumor growth (136). Accordingly, human FAP tissue specimens in 
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dysplatic mycroadenomas epithelium do not maintain BMP2 expression (112). 
The association of these genetic disorders, with the BMPs signaling pathway, was 
confirmed by experiments on transgenic mice, overexpressing the BMP 
antagonist, noggin or mice with conditional inactivation of BMPRIA. These mice 
showed an increased formation of intestinal polyps (113, 127). Moreover, 
conditional inactivation of BMPRII in stroma, led to multiple hamartomatous 
polyp appearance. (137, 138). 
These findings indicate that altered BMPs expression plays an important role in 
aberrant cellular proliferation and tumorigenesis in the human intestine. During 
the last decade, extensive researches were conducted to explain the factors 
involved in the initiation and progression of colorectal cancers in particular, 
BMPs and their signaling pathway have been specially studied. (139, 140). 
Many different groups have demonstrated that several BMPs are suppressive for 
colorectal cancer cells growth (112, 141, 142). Back et al. showed that BMP2 
exerts growth suppression by increasing p21WAF1 protein levels, and not its 
transcription, modulating RAS-ERK pathway (143). 
Moreover, the loss of BMP signaling seems to be correlated to tumor progression, 
indeed, the BMPs expression, is lost from late adenoma to early carcinoma. 
Abnormal CSCs proliferation in CRCs, is due to an abnormal activation of Wnt 
signalling pathway and BMPs signalling inhibition, that promote nuclear beta-
catenin accumulation through PTEN downregulation and iperactivation of PI3K-
Akt pathway (113). Confirming that the BMPs pathway alteration leads to pre-
cancerous lesions (138). 
The TGF-β signalling inactivation plays a key role in CRC development (144), 
indeed, it has been reported that the loss of BMPRII and SMAD4 is frequently 
deleted also in sporadic CRC and that BMPs pathway is inactivated in the 
majority of colorectal tumors (145, 146). This is strongly supported by a 
transgenic mice model in which the inactivation of the BMPs pathway leads to 
polyps formation and up-regulation of Wnt signalling (127). 
Considering BMPs’ role in regulating SCs differentiation and inducing apoptosis 
and differentiation program, it is possible to suppose that CSCs treatment with 
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these molecules could inducing differentiation, make these cells more sensitive to 
conventional chemotherapies.  
Some preliminary studies have been performed on both CSCs of glioblastoma 
(GBM) and CRCs.  
Interestingly, it has been recently demonstrated that in human glioblastoma BMP-
BMPR signalling, controls the activity of normal brain stem cells, and inhibits 
glioblastoma stem like cells (GSLCs) (147). It has been also demonstrated that 
BMP2, BMP4 and BMP7 treatment inhibits sphere forming capacity and induces 
differentiation of CD133+ cells; reducing in vivo glioblastoma tumor growth (147-
149). 
Recently, it has been demonstrated that the treatment of CR-CSCs with BMP4 
induces in vitro differentiation and reduces their tumorigenic potential, sensitizing 
these cells to conventional chemotherapic drugs reducing the tumor size and 
inducing complete long-term regression of colon CSC-derived xenograft tumors 
(94). 
Given the regulatory effect of BMPs on neural stem cells, their progenitors and 
GSLCs, recently, Tate et al. have demonstrated that BMP7 variant (BMP7v) acts 
on proliferation, differentiation, angiogenesis, and in vivo tumorigenicity of 
GSLCs isolated from surgical specimens of primary GBM. In particular, BMP7v, 
decreases proliferation of GSLCs, inducing their differentiation into neuronal- and 
astrocyte cellular phenotypes, and inhibites angiogenic endothelial cord 
formation. These results were confirmed by in vivo analysis of subcutaneous or 
orthotopic tumor models. Their data suggest that BMP7v therapy, directed against 
CSCs and angiogenesis, represents a potentially powerful therapeutic option that 
may improve the poor outcome of conventional treatments (150). 
The current therapeutics strategy target and kill differentiated tumor cells that 
constitute the tumor bulk, failing to affect the rare cancer stem-like cell 
population.  
These data suggest the use BMPs, as alternative therapy, to induce the 
differentiation of CSCs and to make them more sensitive to conventional 
chemotherapy. Since the differentiated tumor cells are more sensitive to 
conventional cancer therapies, therapy differentiative represents another possible 
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therapeutic strategy to inhibit tumor growth by inducing the differentiation of 
CSCs, making them more susceptible to the action of chemotherapeutic agents.  
The induction of CSCs differentiation provides a potentially powerful and novel 
approach to the treatment of cancer disease. 
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AIMS 
 
The high mortality rate of colorectal cancer (CRC) is mainly due to the inefficacy 
of standard treatments to cure the metastatic disease. The recurrence and relapse 
characteristic of this kind of cancer suggest that the only one curative therapy 
could be represented by targeting the subpopulations of tumor cells with 
tumorigenic potential, the so-called, cancer stem cells (CSCs) (151). Several 
studies report that radio-chemotherapy, directed against differentiated cells, 
forming the bulk of tumor cell population, are unable to eradicate the tumorigenic 
and metastagenic population, without obtaining a long-term clinical remission. 
Accordingly, the induction of differentiation, affecting the self-renewal ability of 
CSCs, represents an alternative way to inhibit tumor growth and to sensitize CSCs 
to conventional chemotherapy. The treatment of CSCs towards terminally 
differentiation represent an intriguing concept for future therapy. On the basis of 
these data my project proposed to investigate the role of a stable BMP7 variant 
(BMP7v) on CR-CSCs in order to make these cells more sensitive to conventional 
chemotherapy drugs and to develop a new treatment protocol easily tested in 
preclinical models to design a future appropriate clinical trials. 
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MATERIALS AND METHODS 
 
Tissue collection, isolation and culture of cancer cells 
Human CRC tissues were obtained from patients undergoing to CR resection, in 
accordance with the ethical standards of the institutional committee. Normal colon 
mucosa was obtained from the histologically uninvolved resection. Histological 
diagnosis was based on the morphological microscopic features of carcinoma 
cells, determining the histological type and grade.  
Surgical specimens were intensively washed in PBS solution containing 
antibiotics and incubated overnight in DMEM/F12 (GIBCO) containing penicillin 
(500 U/ml, GIBCO), streptomycin (500 µg/ml, GIBCO) and amphotericin B (1.25 
µg/ml, GIBCO) in order to avoid contaminations. Tumor tissues were 
mechanically and enzymatically digested. Enzymatic dissociation was performed 
using collagenase and hyaluronidase in DMEM for 1 hour at 37° C. Dissociated 
CRC cells were then cultured in presence of serum-free medium supplemented 
with epidermal growth factor (20 ng/mL) and basic fibroblast growth factor (10 
ng/mL, both from Sigma-Aldrich, St. Louis, MO 63103, USA) in non-adherent 
conditions, in ultralow adhesion flasks (Corning, Lowell, MA), to promote the 
growth of CSCs as spheres. These culture conditions allow the selection and 
propagation of tumour spheres, containing immature tumour cells, while non 
malignant or differentiated cells are negatively selected. To achieve in vitro 
differentiation of CSCs, dissociated sphere cells were cultured in DMEM-high 
glucose supplemented with 10% FBS in adherent conditions. These cells were 
conventionally indicated as sphere-derived adherent cells (SDACs). All cell 
cultures were carried out at 37°C in a 5% CO2 humidified incubator. Magnetic 
cell separation was performed on tumour cell populations obtained from 
enzymatic dissociation of CRC specimens using microbeads conjugated with 
CD133/1 (AC133, mouse IgG1, cell isolation kit, Miltenyi). After magnetic 
sorting, viability was assessed using trypan blue exclusion. Quality of sorting was 
verified by flow cytometry with an antibody against CD133/2 (293C3-PE, mouse 
IgG1, Miltenyi) on both CD133+ and CD133− depleted cell population.  
Cell death was evaluated by orange acridine/ethidium bromide staining or by 
CellTiter Glo Assay Kit (Promega) accordingly to manufacturer’s instruction. 
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BMP7v used for this work was produced by Eli Lilly and Company. The 
pharmaceutical development of BMP7v represented the major limitation with its 
suboptimal solubility at neutral pH. Mutations into the N terminus of the BMP7v 
prodomain were introduced to enhance the cleavage of prodomain and mature 
domain. Five point mutations were addicted onto the surface of the mature 
domain, through a random mutagenesis approach, to create a molecule that 
retained the same signaling properties of wild-type BMP7 but had greater 
expression and enhanced biophysical properties such as solubility and stability. 
BMP7v material can be made available to researchers upon request to the Lilly 
authors (152).  
In order to detect the proportion of differentiated and undifferentiated cells, 
dissociated spheres were cultured in stem cell medium in presence of BMP7v 
(100ng/ml) up to 18 days. At different time points, the adherent cells were 
harvested with trypsin and mixed with floating cells. The cell mixture was then 
cytospun and stained for CK20 and CD133. 
To evaluate BMP7v role in differentiation in vitro, the spheres were dissociated 
into single cells and cultured in the presence of BMP7v (100ng/ml) for 48 hours 
or 90 minutes in order to evaluate the p-Smad 1, 5, 8 nuclear traslocation. 
 
Histochemistry and Immunohistochemistry /Immunofluorescence 
Histochemical and immunohistochemical/immunofluorescence analyses were 
performed on 5 µm paraffin-embedded sections of human normal colon and CRC 
tissues or subcutaneous tumor xenografts and cytospuns of freshly sorted cells and 
spheres cells exposed to BMP7v  
The following antibodies were used: BMP7 (164311, mouse IgG2B; R&D 
system), CD133 (AC133, mouse IgGb; Miltenyi), BMPRIA, (87933, mouse 
IgG2b; R&D Systems), BMPR1B (88614, mouse IgG2a; R&D Systems), BMPR2 
(73805, mouse IgG2b; R&D Systems), pSmad 1,5,8 (rabbit polyclonal; CST), 
cytokeratin 20 (Ks20.8, mouse IgGa; Dako Cytomation), p21(#2947, Rabbit IgG; 
CST), E-cadherin (rabbit polyclonal; CST), Vimentin (#39325, Rabbit; CST), 
Beta-catenin (H102, rabbit polyclonal; Santa Cruz Biotechnology), CD166 
(MOG/07, Mouse Monoclonal Antibody; Leica), Lgr5 (RB 14211, Rabbit Ig; 
ABGENT) Ki67 (MIB-1, mouse IgG1; Dako Cytomation), CD31 (clone JC70A, 
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mouse IgG1Kappa; Dako ytomation), VEGFR2 (goat IgG; R&D System) or 
isotype-matched controls at appropriate dilutions. 
For immunohistochemistry (IHC) the dewaxed slides were heated for 1 min at 
450 W and 5 min at 100 W in a microwave oven in 0.1M citrate buffer pH 6.0 or 
pH 9.0 only for KI67 staining. For cytoplasmatic epitopes detection, samples were 
permeabilized with 0.1% TritonX-100 in PBS for 10 min sections and after the 
slides were incubated with Tris-buffered saline (TBS) containing 10% AB human 
serum to block unspeciﬁc binding. After elimination of excess serum the sections 
were exposed overnight at 4°C to speciﬁc Abs against BMP7, CD133, CD166, 
Beta-catenin, Lgr5, Ki67, CK20, CD31, VEGFR2 or isotype-matched controls at 
appropriate dilutions. Following exposure to primary Abs, sections were treated 
with biotinylated anti-mouse- rabbit and anti goat immunoglobulins, washed in 
PBS and then incubated with streptavidin peroxidase (LSAB 2 Kit; Dako 
Cytomation or Vectastain kit; Vector). Stainings were detected using 3-amino-9-
ethylcarbazole (AEC) chromogen. Counterstain of nuclei was performed using 
aqueous hematoxylin (Sigma). 
For hematoxylin and eosin (H&E) staining, dewaxed sections were stained in 
Hematoxylin (Sigma) for 1 minutes, washed in water and then exposed for 30 
seconds to eosin (Sigma). Stained sections were dehydrated and mounted with 
syntetic resin. 
For Azan Mallory, sections were stained with azocarmine G (Sigma) for 1 hour 
and with 5% of phosphovolframic acid for an additional hour. Then, sections were 
stained with aniline blue/orange G (Sigma) and mounted in synthetic resin. 
All IHC images were analyzed with Imaging Analyzer Software 
Apoptotic events were determined by TUNEL labeling  using In Situ Cell Death 
Detection, AP Kit (Boehringer Mannheim) (roche). DNA strand breaks were 
detected by 5-bromo-4-chloro-3-indolyl-phosphate (BCIP, Dako Cytomation) 
substrate.  
Immunofluorescence stainings were performed on 5-µm-thick embedded sections 
of human CRC tissues, on cytospun freshly sorted cells, spheres cells allowed to 
differentiate in 10% FBS or after exposure to BMP7v. Cells were fixed in 2% 
PFA for 20 min at 37°C. For cytoplasmatic epitopes detection, samples were 
permeabilized with 0.1% TritonX-100 in PBS for 10 min, blocked with 3% BSA 
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for 30 min and exposed overnight at 4°C to antibodies against BMP7, CD133, 
BMPRIA, BMPRIB and BMPRII, p-SMAD1,5,8, CK20, p21, E-cadherin, 
Vimentin and beta-catenin or isotype-matched controls at appropriate dilutions. 
Then, cells were treated with FITC or Rhodamine anti-mouse or anti-rabbit 
antibodies (Molecular Probes, Inc.) plus RNase (200 ng/ml, Sigma). Nuclei were 
counterstained using Toto-3 iodide (642/660, Molecular Probes). Confocal 
analysis was used to acquire fluorescence stainings. 
 
RNA isolation and Real-time PCR 
Total RNA from cell pellet was obtained using the Rneasy Mini Kit (Qiagen 
GmbH), the residual amounts of DNA remaining was removed using the RNase-
Free DNase according to manufacturer’s instructions. The yield of the extracted 
RNA was determined by measuring the optical density at 260 nm by Nanodrop 
ND-1000 (Nanodrop, Wilmington, DE). 
1 µg of total RNA was retro-transcribed using High-Capacity cDNA Archive Kit 
(Applied Biosystems) according to manufacturer’s instructions. PCR 
amplification and detection of the PCR amplified gene products were performed 
with the SYBR Green PCR master mix (SuperArray Bioscience, Frederick, MD) 
All amplification reactions were done in triplicate, and the relative quantitation of 
gene expression was calculated using the comparative Ct method (ΔΔCt). Levels 
of mRNA expression were expressed after normalization with endogenous 
control, GAPDH. For SYBR green chemistry, the following primers were 
purchased from MWG: BMPR1A forward primer 5' GTC ATA CGA AGA TAT 
GCG TGA GGT TGT 3', BMPR1A reverse primer 5' ATG CTG TGA GTC TGG 
AGG CTG GAT T 3, BMPR1B forward primer 5' AAG GCT CAG ATT TTC 
AGT GTC GGG A 3', BMPR1B reverse primer 5' GGA GGC AGT GTA GGG 
TGT AGG TCT TTA TT 3', BMPR2 forward primer 5' GTG ACT GGG TAA 
GCT CTT GCC GTC T 3', BMPR2 reverse primer 5' GCA GGT TTA TAA TGA 
TCT CCT CGT GGT 3', GAPDH forward primer 5' GCT TCG CTC TCT GCT 
CCT CCT GT 3', GAPDH reverse primer 5' TAC GAC CAA ATC CGT TGA 
CTC CG 3'.  
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Flow cytometry 
Flow cytometry was performed on freshly purified colon cancer cells after 
magnetic CD45+ cells depletion, SDAC and dissociated sphere cells untreated and 
treated with BMP7v. Cell preparations were fixed in 2% paraformaldehyde for 10 
min at 37°C and permeabilized by 0.1% Triton-X 100 for 10 min at 4°C to detect 
cytoplasmatic epitopes. Cells were washed twice with 0.5% bovine serum 
albumin (BSA, Sigma) in PBS and exposed to antibodies against CD133/2 
(293C3-PE, mouse IgG2b, Miltenyi), CD133/1 (AC133, mouse IgG2b, Miltenyi), 
CK20 (Ks20.8, mouse IgG2a, DAKO Cytomation). Samples were then incubated 
with FITC-conjugated anti-mouse or anti-rabbit antibodies (Molecular Probes). 
Cells were subjected to flow cytometry analysis using a FACSCalibur cytometer 
and Cell Quest Software (Becton Dickinson). Only cells with staining intensities 
above the maximal level of isotype-matched controls were defined as positive 
cells. 
Cell cycle analysis was performed on dissociated sphere cells untreated and 
treated with BMP7v for 48 hours and SDACs. The cells were washed in PBS and 
fixed in ice-cold 70% ethanol at 4°C overnight and then incubated with PBS 
containing propidium iodide (50 µg/ml, Sigma), sodium citrate (3.8 Mm, Sigma) 
and RNase (10 µg/ml, Sigma) at 37°C for 30 minutes. Samples were analyzed 
using a flow cytometer (BD Biosciences). 
PKH26 (Sigma) staining was performed, according to manufacturer’s 
instructions, on dissociated sphere cells, untreated and treated with BMP7v 
(100ng/ml) for 48 hours, up to 14 days, at different time points these cells were 
harvested for the FACS analysis,  
 
Protein isolation and immunoblotting 
Cell pellets were re-suspended in ice-cold NP40 lysis buffer [50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 1 mM EGTA, and 1% NP40] containing proteases and 
phosphatases inhibitors and fractioned on SDS-polyacrylamide gels and blotted 
on nitrocellulose membranes. Membranes were blocked for 1 hour with nonfat 
dry milk in TBS containing 0.05% Tween 20 and successively incubated with 
antibodies specific against PTEN (17A, mouse IgMk, Neomarkers), AKT (rabbit 
polyclonal, CST), p-AKT (Ser 473, rabbit polyclonal, CST), GSK3ß (rabbit 
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polyclonal, CST), p-GSK3ß (Ser9, rabbit polyclonal, CST) and beta-actin 
(JLA20, mouse IgM, Calbiochem) used as loading control. Membranes were then 
washed, incubated for 1 hour with horseradish peroxidase-conjugated anti-mouse, 
anti-rabbit or anti-goat immunoglobulins (Amersham Biosciences) and developed 
with a chemiluminescence detection system (SuperSignal West Pico/Dura 
Extended duration Substrate, Pierce Biotechnology). Densitometric analysis of 
protein expression level was performed by Vision Works LS (UVP). Results were 
expressed as protein/beta-actin OD ratio. 
 
Clonogenic and colony forming assays 
Dissociated sphere cells untreated and treated with BMP7v for 48 hours were 
plated in presence of stem cell medium, on ultra-low-adhesion 96-well plates at a 
concentration of a single cell per well. Wells containing either none or more than 
one cell were excluded for this analysis, but these valors was used to calculate the 
cancer stem cell frequency, with ELDA software. 
Colony forming was performed on dissociated sphere cells untreated and treated 
with BMP7v, 5FU+Oxaliplatin alone or in combination. Cells were plated on 
Agarose Sea Plague Agar (Invitrogen), and maintained up to 21 days at 37°C in 
presence of 5% CO2.  The colonies were stained with 10% Cristal Violet. 
 
Invasion assay 
Cell migration capacity was assessed using growth factor–depleted matrigel–
coated (BD Biosciences) transwell insert. Dissociated sphere cells (2x103) 
untreated and treated with BMP7v 100ng/ml for 48 hours were plated into 
matrigel-coated transwell of 8 µm pore size (Corning). Supernatant of NIH-3T3 
cells, cultured in stem cell medium was used as chemoattractant in the transwell 
lower part. Migration was observed  and counted microscopically up to 96 hours. 
 
RT2 ProfilerTM PCR Array.  
The RT2 Profiler PCR array was assessed for genes related to Wnt targets (PAHS-
243ZR-12; SuperArray Bioscience). It was used to simultaneously examine the 
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mRNA levels of 89 genes closely associated with Wnt pathway, including five 
"housekeeping genes" in 96-well plates following the manufacturer's protocol. 
Cycle threshold values were calculated for all the genes present on the array and 
normalized using the average of 5 housekeeping genes (ACTB, B2M, HPRT1, 
RPLP0 and GAPDH). RT2 Profiler PCR Array Data Analysis was represented by 
clustergrams based on Pearson’s Correlation of 2^ (ΔCt). 
 
Animals and tumor model 
Mice were obtained from Charles River Laboratories (Milan, Italy) and 
maintained according to institutional guidelines of the University of Palermo 
animal care and committee. Dissociated CRC sphere cells (5x105) were implanted 
subcutaneously (s.c.) with matrigel GF reduced (BD Biosciences) at a 1:1 ratio in 
a total volume of 100 µL into the flank of five-to-six week old NOD-SCID mice. 
Tumor mass size was calculated according to the formula: (π/6) x larger diameter 
x (smaller diameter)2. When tumors were palpable the mice were treated three 
times a week by intraperitoneal injection of BMP7v for three weeks at different 
concentrations: 50, 5, 0.5 and 0.05µg/kg, and PBS as control, in order to test the 
efficacy dose.  
Then the other set of mice were treated three times a week for three weeks by 
intraperitoneal injection (IP) of PBS, as control, BMP7v (50µg/kg) alone or in 
combination with 5FU and Oxaliplatin. (5-FU: 15 mg/kg/day for 2 days a week 
for 3 weeks; and Oxa: 0.25 mg/kg once a week for 3 weeks). 
Histological examination, analysis of differentiation, incidence of cell death and 
mitotic index were determined on tumor xenografts using AC133, CK20, TUNEL 
and Ki67 staining. 
To test the BMP7v activity as second line treatment, when the tumor xenografts 
obtained as previous described, were palpable, the standard adjuvant treatment, 
Oxaliplatin (0.25 mg/kg once a week for 3 weeks) and 5-FU (15 mg/kg/day for 2 
days a week for 3 weeks) was performed intraperitoneally on eight mice for 
group. After this first line of treatment with 5FU plus Oxaliplatin alone for two 
weeks when tumor re-growth, the follow IP treatments were performed: PBS, 
5FU+Oxaliplatin, BMP7v and BMP7v+5FU+Oxaliplatin, in a standard protocol 
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for three weeks. The tumor xenografts obtained after 13 weeks from injection 
were used for histological examination. 
 
Endothelial tube formation assay 
The effects of BMP7v on in vitro endothelial tube formation were evaluate using 
HUVEC, obtained from Lonza (Clonetics, Verviers, Belgium) and grown in 
endothelial growth medium (EGM) according to supplier’s information. HUVEC, 
pretreated with BMP4 (2nM R&D System) and BMP7v (100ng/ml) for 24, 48, 72 
hours, were plated (70,000 cells/well) in Matrigel-coated 24 well plate (BD 
Bioscience), and incubated up to 5 hrs at 37°C. Endothelial tube formation, 
evaluated by phase-contrast microscopy, was photographed at different time 
points and the cables length was measured manually with the IMAGE-J software. 
 
Statistical analysis 
Data were expressed as mean ± standard deviation of the mean. 
Immunohistochemical  scores were calculated from the positivity observed on 
paraffin-embedded engrafted tumor tissues counted by two independent 
observers.  
Statistical significance was determined by Analysis of Variance (one-way or two-
way) with Bonferroni post-test. Results were considered significant when p values 
were less than 0.05. * indicates P<0.05, ** indicate P<0.01, ***  indicate 
P<0.001. 
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RESULTS 
 
BMP7 is widely expressed in colo-rectal cancer tissue but not in colo-rectal 
cancer stem cells 
Human colo-rectal cancer (CRC) specimens were provided by the Surgical 
Department of Policlinico “Paolo Giaccone”, Palermo.  
These tumors and their normal counterpart (obtained from the edge of the resected 
specimen) were analysed for BMP7 expression with immunohistochemistry: CRC 
specimens widely expressed BMP7, compared to their normal counterpart 
(Fig.4A).  
Expression of this cytokine was also analysed with immunofluorescence (IF) on 
paraffin embedded cancer tissue: BMP7 was localized along the upper part of the 
crypt, with the exception of the base of the crypt where stem cells reside (Fig.4B). 
These findings prompted us to investigate whether there is differential expression 
of BMP7 between cancer stem cells (CSCs) and their differentiated counterpart 
using our in vitro models, i.e. sphere cells and sphere-derived adherent cells 
(SDACs), respectively. While SDACs displayed high levels of BMP7 expression, 
sphere cells showed very low positivity.  
We also analyzed BMP7 expression in CR-CSCs sorted for CD133 positivity, a 
known CSC marker: IF analysis showed that BMP7 is exclusively expressed by 
CD133- cells (Fig.4C-D). 
All in vitro experiments shown in this report were conducted in three different cell 
lines. The images are from one cell line, but are representative of results obtained 
for all three cell lines. 
These data suggest a correlation between BMP7 expression and differentiation of 
CRC cells, and therefore a possible role in CSCs differentiation.  
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Fig.4. CD133+ CR-CSCs do not express BMP7. A) Immunohistochemical analysis for BMP7 on 
normal and tumoral colon paraffin-embedded sections. Nuclei are revealed by hematoxylin 
staining (blue). B) Confocal microscopy analysis of BMP7 (green) on CRC paraffin-embedded 
tissue. Nuclei were counterstained with Toto-3 (blue). C) Representative images of 
immunofluorescence analysis of BMP7 (green) in sphere cells (Spheres) and SDACs. Nuclei were 
counterstained with Toto-3 (blue). D) Representative images of immunofluorescence analysis of 
BMP7 (green) on CD133- and CD133+ CRC cells sorted from the sample as in C. Nuclei were 
counterstained by Toto-3 (blue). 
 
 
 
BMP7v in vitro administration activates the BMP signaling pathway in CR-
CSCs. 
To evaluate the possible use of BMP7v as a differentiative agent of CSCs, we 
analysed the expression of BMP receptors through real-time PCR and IF analysis.  
Both CRC sphere cells and SDACs expressed BMPR1A, BMPR1B and BMPR2 
(Fig.5A). 
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In order to verify the BMPRs functionality in CR-CSCs, we evaluated p-SMAD1-
5-8 localization with IF after treatment with BMP7v (100ng/ml): activation of the 
BMP7 pathway was confirmed by the prevalent p-Smad1,5,8 nuclear 
translocation following treatment (Fig.5B-C).  
Western blot analysis of downstream targets to the BMP7 pathway are consistent 
with these findings (Fig.5D). 
These results indicate that exogenous addition of BMP7v can activate the 
canonical BMP signaling pathway in CR-CSCs.  
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Fig.5. BMP7v administration activates the canonical signaling pathway in CR-CSCs. A) 
Relative quantification of BMPR1A, BMPR1B, and BMPR2 mRNA expression levels in sphere 
cells (Spheres) and SDACs. B) Representative images of immunofluorescence analysis of 
BMPR1A, BMPR1B, and BMPR2 (green) in sphere cells and SDACs. Nuclei were counterstained 
with Toto-3 (blue). C) Representative images of confocal microscopy analysis of pSmad1,5,8 
(green) in sphere cells, untreated or treated with BMP7v for 90 minutes or 48 hours. Nuclei were 
stained with Toto-3 (blue). D) Densitometric analyses of protein expression levels of AKT, p-
AKT, PTEN , GSK3β and p- GSK3β in sphere cells, untreated or exposed to BMP7v for 48 hours, 
and SDACs. Loading control was assessed by β-actin.  
 
 
 
BMP7v induces in vitro differentiation in CR-CSCs and reduces the 
percentage of CD133+ cells 
To evaluate the role of BMP7v in inducing differentiation, we tested whether 
sphere cells could be forced to differentiate upon exposure to the morphogenetic 
factor. CRC sphere cells were cultured in the presence of BMP7v or 10% FBS. 
BMP7v alone induced a rapid differentiation of CR-CSCs, evaluated by plastic 
adherence and acquisition of the typical differentiated appearance, i.e. large size 
and polygonal shape (Fig.6A).  
Accordingly, BMP7v treatment reduced the percentage of CD133+ and increased 
CK20 expression in CR-CSCs (Fig.6B-C). 
Reduction of the CD133+ cells following 48 hours of BMP7v treatment was also 
confirmed by flow cytometry (Fig.6D). 
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Fig.6. BMP7v promotes in vitro differentiation of CR-CSCs. A) Representative images of 
phase-contrast microscopy of dissociated sphere cells, untreated or treated with BMP7v up to 18 
days. B) Percentage of CK20+ sphere cells, untreated or treated with BMP7v up to 18 days. C) 
Percentage of CD133+ sphere cells, untreated or treated with BMP7v. D) Representative flow 
cytometry profile of CD133 expression in sphere cells, untreated or treated with BMP7v for 48 
hours. 
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BMP7v reduces self-renewal of CR-CSCs  
To evaluate the effect of BMP7v treatment on CR-CSCs self renewal capacity, we 
performed the in vitro colony forming assay. BMP7v, given for 48 hours, reduced 
the CR-CSCs sphere forming capacity.  
We also tested the effect of combining BMP7v to standard chemotherapy 
(5FU+Oxa): this treatment resulted in a more significant reduction of clonogenic 
capacity compared to chemotherapy alone in CR-CSCs. 
To further test the CR-CSC sensibility to BMP7v, one week after the first step of 
treatment, the cells were re-treated: this treatment reduced the colony forming 
efficiency even more drastically (Fig.7A-B).  
As p21 seems to be a key regulator of CR-CSC self renewal, we also evaluated its 
cellular localization with IF: BMP7v treatment induces depletion of nuclear p21, 
confirming the induction of cell cycle progression, with consequent cancer stem 
cell clone exhaustion (Fig.7C). 
We showed that BMP7v treatment not only reduces CR-CSCs self-renewal but 
also potentiates the effect of standard chemotherapy. 
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Fig.7. BMP7v reduces self renewal of CR-CSCs. A) Representative colony forming assay of 
sphere cells, untreated or treated with 5FU+Oxaliplatin (chemo), BMP7v alone (BMP7v), 
BMP7v+5FU+Oxaliplatin (BMP7v+chemo), for 48 hours; these treatments were performed once 
as a 1st line or repeated after one week as a 2nd line of treatment. B) Percentage of colony forming 
efficiency in sphere cells, untreated or treated as in A. C) Representative images of confocal 
microscopy analysis of p21 (green) in sphere cells, untreated and treated with BMP7v for 48 hrs. 
Nuclei were stained with Toto-3 (blue). 
 
 
BMP7v induces CR-CSCs to exit from quiescence 
We then evaluated the effect of BMP7v on cell cycle distribution. FACS analysis 
revealed that 48 hours of BMP7v treatment, unlike to BMP4, induced a 
significant increase in the percentage of cells in the G2/M phase, with a reduction 
of cells in G0/G1.  
Interestingly, the BMP7v induced cell cycle distribution in sphere cells was 
similar to the baseline SDACs profile (Fig.8A-B). 
To evaluate the effect of BMP7v on proliferation of CR-CSCs, we performed 
PKH26 staining: treatment induced a reduction of PKH26 high cells, confirming 
the induction of proliferation in a time dependent manner (Fig.8C-D). 
These data suggest that, in addition to differentiation induction, BMP7v treatment 
displays an unexpected proliferative effect.  
This cytokine drives different cell subpopulations present in sphere cultures to 
exit from the quiescent state, characteristic of stem cells, thus making them more 
sensitive to standard chemotherapies. 
Taken together, these in vitro results indicate that BMP7v treatment is able to 
reduce stemness of CR-CSCs.  
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Fig.8. BMP7v induces CR-CSCs to exit from quiescence. A) Representative cell-cycle profile 
of sphere cells, untreated or treated with BMP7v for 48 hours, and SDACs. B) Cell-cycle 
distribution of sphere cells treated as in A. C) Representative PKH-26 profile of sphere cells, 
untreated or treated with BMP7v up to 14 days. D) Percentage of PKH-26 high cells treated as in 
C. 
 
 
BMP7v reduces the mesenchymal CR-CSCs traits 
Given the link between CSCs, epithelial-mesenchymal transition (EMT) and 
metastasis, we tested the effect of BMP7v treatment on CR-CSCs invasive 
capacity, using a transwell migration assay: BMP7v drastically reduces CR-CSC 
motility and invasiveness (Fig.9A).  
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We then analysed expression of EMT markers, such as E-caderin, Vimentin and 
beta-catenin: BMP7v suppressed the mesenchymal trait, inducing E-cadherin 
expression and cytoplasmic localization of beta-catenin, while silencing Vimentin 
(Fig.9B). 
Given the role of the Wnt pathway in EMT, a Wnt signaling trascriptional profile 
was performed on CR-CSCs after 48 hours of BMP7v treatment to verify its 
action on regulation of Wnt targets: results revealed a strong regulation of Wnt 
targets involved in stemness and migration.  
BMP7v induced upregulation of Wnt inhibitors such as SFRP2 and Axin2, 
associated with down regulation of stem cell markers, such as SOX2 e Nanog. In 
addition, the treatment reduced expression of migration regulator genes, such as 
Met and MMP2 and 7 (Fig.9C).  
These results confirm the induction of differentiation via the Wnt pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.9. BMP7v reduces the mesenchymal CR-CSCs traits. A) Invasion assay of sphere cells, 
untreated or treated with BMP7v for 48 hours at different time points up to 96 hrs. B) 
Representative images of confocal microscopy analysis of E-cadherin, Vimentin and Beta-catenin 
(green) in sphere cells, untreated or treated as in A. Nuclei were stained with Toto-3 (blue). C) 
Wnt target card clustergram on sphere cells untreated or treated as in A. 
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BMP7v in combination with standard chemotherapy reduces CR-CSCs 
tumor growth in vivo 
To evaluate the effects of BMP7v on CR-CSCs tumor growth in vivo, different 
concentrations were administered intraperitoneally (IP) three times a week.  
Three to four weeks after subcutaneous injection of sphere cells, palpable tumors 
were observed in immuno-compromised mice. BMP7v treatment was started at 
different doses listed below: 50, 5, 0.5 and 0.05µg/kg. 
The results showed a reduction in tumor size and a notable necrotic effect 
confirmed by Azan Mallory staining on paraffin embedded xenografts sections: 
these effects were more pronounced in the 50µg/kg group (Fig.10A-C). 
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Based on these findings, we decided to use 50µg/kg in combination with standard 
chemotherapy, to evaluate whether BMP7v could enhance its cytotoxic effect in 
vivo.  
Tumors were obtained injecting Smad4-wt, Smad4-null and Smad4-null PI3K/CA 
sphere cells. They were then exposed to Oxaliplatin plus 5-FU alone or in 
combination with intraperitoneal injection of PBS or BMP7v. 
Combined treatment resulted in a considerable reduction of tumor growth in 
Smad4-wt and Smad4-null, while it was less effective in Smad4 null harboring 
PI3KCA mutation.  
BMP7v alone gave a more pronounced growth delay than standard chemotherapy 
(Fig.10D). 
Histological analysis of xenografts treated with BMP7v plus chemotherapy 
showed an high percentage of dying cells and large areas of fibrosis, highlighted 
by TUNEL staining (Fig.10E). 
BMP7v plus chemotherapy treated tumors showed lower expression of CD133, 
CD166, β-catenin, Lgr5 and Ki67, with a significant increase of CK20 compared 
to control, suggesting anti-proliferative and pro-differentiative effects in vivo 
(Fig.10E-L).  
Our findings confirm the rationale for combining a pro-differentiation agent with 
chemotherapy drugs, supporting the use of BMP7v in colorectal cancer patients. 
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Fig.10. BMP7v in combination with standard chemotherapy reduces CR-CSCs tumor 
growth in vivo. A) Size of subcutaneous tumors following injection of sphere cells. When tumor 
xenografts were palpable immuno-compromised mice were treated intraperitoneally three times a 
week with BMP7v (50, 5, 0.5 or 0.05 ug/Kg) or with PBS as control. B) Percentage of necrosis 
evaluated on paraffin-embedded sections of xenografts, untreated or treated as in A. C) 
Representative Azan-Mallory staining on paraffin embebbed xenografts untreated (PBS) or treated 
as in A. D) Size of subcutaneous CRC xenografts derived from injection of sphere cells. Mice 
were untreated (PBS) or treated intraperitoneally with BMP7v (50ug/Kg), 5-FU plus Oxaliplatin 
alone or in combination with BMP7v. The arrows indicate the starting point of treatment. Data 
were obtained on three different cell lines .E) Immunohistochemical analysis of CD133 and 
TUNEL (dark blue) revealed by AEC (red) on paraffin-embedded sections of xenografts obtained 
as in D. Nuclei are revealed by hematoxylin staining (blue). Arrowheads indicate TUNEL positive 
cells. F) Percentage of CD133+ cells evaluated on paraffin-embedded sections of tumors, untreated 
(PBS) or treated as in D. G) Percentage of TUNEL positive cells evaluated on paraffin-embedded 
sections of tumors untreated (PBS) or treated as in D. H) Immunohistochemical analysis of 
CD166, beta-catenin and Lgr5 revealed by AEC (red) on paraffin-embedded sections of xenografts 
obtained as in D. Nuclei are revealed by hematoxylin staining (blue). Arrowheads indicate CD166, 
beta-catenin and Lgr5 positive cells. I) Immunohistochemical analysis of Ki67 revealed by AEC 
(red) on paraffin-embedded sections of xenografts obtained as in D. Nuclei are revealed by 
hematoxylin staining (blue). Arrowheads indicate Ki67 positive cells. (upper: low magnification; 
lower: high magnification) J) Percentage of Ki67 positive cells evaluated on paraffin-embedded 
sections of tumors untreated (PBS) or treated as in D. K) Immunohistochemical analysis of CK20 
revealed by AEC (red) on paraffin-embedded sections of xenografts obtained as in D. Nuclei are 
revealed by hematoxylin staining (blue). (upper: low magnification; lower: high magnification) L) 
Percentage of CK20 positive cells evaluated on paraffin-embedded sections of tumors, untreated 
(PBS) or treated as in D. 
 
 
BMP7v has a strong anti-angiogenic effect in vivo 
Since BMP7v treatment resulted in a considerable growth delay associated with a 
potent necrotic effect, we investigated further its anti-angiogenic potential. 
Xenografts were exposed to BMP7v or BMP4, another member of the BMP 
family with an anti-tumour activity.  
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Histological examination showed a significant reduction of human CD31 and 
VEGFR2 expression following BMP7v, but not BMP4 treatment (Fig.11A-C). 
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We also performed an endothelial tube formation assay using endothelial cells 
from the umbilical vein (HUVEC): BMP7v affected the ability to form vessels 
after 48 hrs of treatment, while this was not observed for BMP4 (Fig.11D-F). 
These findings confirm a specific anti-angiogenic effect of BMP7v in colorectal 
cancer xenografts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11. BMP7v has a strong anti-angiogenic effect. A) Immunohistochemical analysis of CD31 
and VEGFR2 revealed by AEC (red) on paraffin-embedded section of xenografts obtained after 
PBS or BMP7v treatment (50ug/Kg). Nuclei are revealed by hematoxylin staining (blue). B) 
Percentages of CD31 and VEGFR2 expression evaluated on paraffin embedded sections of tumors 
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treated as in A. C) Immunohistochemical analysis of CD31 and VEGFR2 revealed by AEC (red) 
on paraffin-embedded section of xenografts obtained after intra-tumoral injection of PBS or BMP4 
loaded beads. Nuclei are revealed by hematoxylin staining (blue). D) Representative images of 
phase-contrast microscopy of endothelial tube formation assay. Huvec cells, untreated (EGM 
medium as control) or pretreated with BMP7v (100ng/ml) at different time points. E) Measure 
(pxl) of total tube length obtained with Huvec treated as in D. F) Representative images of phase-
contrast microscopy of endothelial tube formation assay. Huvec cells untreated (EGM medium as 
control) or pretreated with BMP4 (2nM) and BMP7v (100ng/ml) at different time points.  
 
 
BMP7v as second-line treatment shows significant anti-tumor activity in 
xenografts refractory to chemotherapy 
To test the activity of BMP7v as second line treatment, first line treatment with 
5FU plus Oxaliplatin was administrated for two weeks. After tumour re-growth, 
mice were treated with: PBS, 5FU+Oxaliplatin, BMP7v or 
BMP7v+5FU+Oxaliplatin, for three weeks. BMP7v alone showed greater efficacy 
compared to combined treatment in tumor xenografts previously treated with 
standard chemotherapy (Fig.12A). 
Hystological examination of xenografts, obtained 13 weeks after injection, 
revealed a strong necrotic effect. This was also confirmed with Azan Mallory 
staining (Fig.12B-C). 
These results further support the possible use of BMP7v in colorectal cancer, 
providing evidence for its efficacy in pre-treated patients. 
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Fig.12. BMP7v shows an anti tumor activity as second line treatment in xenografts 
refractory to chemotherapy. A) Size of subcutaneous CRC xenografts derived from injection of 
sphere cells. Mice were untreated (PBS) or treated intraperitoneally with 5-FU+Oxaliplatin for two 
weeks. After tumor re-growth mice were treated with PBS, BMP7v (50ug/Kg), 5-FU+Oxaliplatin 
alone or combination. B) H&E staining of paraffin-embedded sections of xenografts obtained as in 
A. C) Percentage of necrosis evaluated on paraffin-embedded sections of xenografts untreated 
(PBS) or treated as in A.  
 
  
40x 40x 40x 40x
PBS BMP7v 5FU/Oxa BMP7v+5FU/Oxa
B 
0
20
40
60
80
100
Ne
cr
os
is
 (%
)
C 
 52 
DISCUSSION AND CONCLUSIONS 
 
Current therapies mostly hit the differentiated cells, sparing the tumorigenic 
population which is responsible for the tumor relapse. Although clinical protocols 
are traditionally directed against the bulk of tumor cell population, increasing 
evidence suggests that curative therapies can be established only by targeting the 
subpopulations of tumor cells with tumorigenic potential. Several reports indicate 
that chemotherapy is more active on differentiated cells and generally ineffective 
against the tumorigenic population. In fact, traditional debulking agents often fail 
to produce long-term clinical remission and tumor relapses as a result of the 
inability to target cancer initiating cells (151). 
The induction of differentiation affecting the self-renewal ability of CSCs 
represents an alternative way to inhibit tumor growth and to sensitize CSCs to 
conventional chemotherapy drugs.  
According to recent publications, the tumor-initiating cells have stem like 
characteristics such as abilities of self-renewal, differentiation and invasion. 
Several research groups have identified tumorigenic populations with stem-like 
features in CRC (28-30, 73, 76, 80). These cellular subpopulation is able to 
promote tumor growth and is considered as an optimal cellular target to obtain 
effective therapies.  
Many reports suggest that the balance between self-renewal and differentiation in 
normal stem cells results deregulated in CR-CSCs. 
Indeed, the activation of Wnt signaling plays a key role in maintaining the normal 
stem cell population in the gut and promoting self-renewal of CR-CSCs (153-156) 
but also the cytokines, released in the microenvironment, contribute significantly 
to maintain the undifferentiated status and clonogenic activity of the tumorigenic 
cells (157). 
Thus, the differentiation therapy could represent a considerable therapeutic option 
for the treatment of colon cancer, inhibiting CSCs self-renewal ability and 
eradicating the tumor-driving cell population. Although this approach does not 
directly kill the cancer cells, it could make the conventional therapies more 
effective in the eradication of the tumor bulk.  
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For years retinoic acid has been used in the treatment and differentiation of 
promyelocytic leukemia, thus validating this concept (158). The pro-
differentiative effect of Bone Morphogenetic Protein 4 (BMP4) has been already 
proposed as a therapeutic option for human glioblastoma and colorectal cancer 
(147, 158-160) 
Moreover these treatments enhanced the antitumor activity of chemotherapeutic 
drugs, whose concomitant administration is able to induce a complete therapeutic 
response, also after treatment interruption. Thus supporting the combined use of 
differentiative and cytotoxic agents for cancer therapy. Accordingly, the induction 
of differentiation, affecting the self-renewal ability of CSCs, represents an 
alternative way to inhibit tumor growth and to sensitize CSCs to conventional 
chemotherapy.  
On the basis of these data, this work proposed to investigate the role of a stable 
BMP7 variant (BMP7v) on CSCs purified from CRC sample, in order to make 
these cells more sensitive to conventional chemotherapy drugs and to develop a 
new treatment protocol easily tested in preclinical models to design a future 
appropriate clinical trials. 
This study identifies, the use of BMP7v, as new potential therapeutic approach 
that activates CRC differentiation program. As previously described, the pro-
differentiation activity of BMPs, is perfectly detectable in normal gut in which 
these molecules are expressed following a decreasing gradient from the intestine 
lumen up to the crypt, thus limiting the stem cell expansion at the bottom of the 
crypts promoting the intestinal epithelial cell differentiation along the upper part 
of the crypts (113, 114).  
The present data show that all CRC specimens analysed, widely express BMP7, 
compared to their normal counterpart and its expression is limited to the 
differentiated progeny of CRC epithelial cells, which constitute the major 
population of the tumor mass. Here we demonstrated that BMP7 is localized 
along the upper part of the crypt, with the exception of the base of the crypt where 
stem cells reside. On the contrary, its expression is undetectable in the CD133+ 
CR-CSCs fraction. BMP7 results exclusively expressed by CD133- cells or in 
their differentiated counterpart, the sphere-derived adherent cells (SDACs). 
Although both CRC sphere cells and SDACs express BMPR1A, BMPR1B and 
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BMPR2. These results suggest a correlation between BMP7 expression and 
differentiation of CRC cells, and therefore a possible role in CSCs differentiation.  
The activation of the BMP signalling pathway was confirmed by the prevalent p-
Smad1,5,8 nuclear translocation following BMP7v treatment, as confirmed by 
analysis of downstream protein targets. Accordingly, BMP7v treatment increased 
PTEN levels inhibiting PI3K/AKT survival pathway confirming its differentiative 
role on CR-CSCs (161). 
BMP7v treatment induced a rapid differentiation of CR-CSCs, morphologically 
evaluated by plastic adherence and acquisition of the typical differentiated 
phenotype, into large and polygonal colonic cells. Consequently, this treatment on 
CR-CSCs reduced the percentage of CD133+ subpopulation increasing the CK20 
expression, a typical markers of epithelial colonic differentiation. 
BMP7v, also reduce the sphere forming capacity, and maintain this capacity also 
after a first step of treatment, showing that this second treatment reduces the 
colony forming efficiency even more drastically. Moreover BMP7v not only 
decreases CR-CSCs self-renewal but also potentiates the effect of standard 
chemotherapy. 
Taken together, these in vitro results indicate that this cytokine drives the different 
cell subpopulations present in sphere cultures to exit from the quiescent state, 
characteristic of stem cells, thus making them more sensitive to standard 
chemotherapies, as showed by cell cycle analysis. The BMP7v treatment in fact 
increased the percentage of cells in the G2/M phase, reducing the cells in G0/G1, 
confirming that BMP7v treatment is able to reduce CR-CSCs stemness trait.  
According to these data the treatment reduces CR-CSC motility and invasiveness, 
underlining the link between CSCs, epithelial-mesenchymal transition (EMT) and 
metastasis, as showed by the analysis of putative EMT markers: BMP7v 
suppressed the mesenchymal trait, inducing E-cadherin expression and 
cytoplasmic localization of beta-catenin, reducing Vimentin expression. 
To confirm the correlation between BMP and Wnt pathways suggested by western 
blotting analysis a Wnt signaling trascriptional profile was performed on CR-
CSCs after 48 hours of BMP7v treatment: BMP7v induced up-regulation of Wnt 
inhibitors such as SFRP2 and Axin2, associated with down regulation of stem cell 
markers, such as SOX2 e Nanog. In addition, the treatment reduced expression of 
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migration regulator genes, such as Met and MMP2 and 7. These results confirm 
the induction of differentiation via the Wnt pathway. 
The clinical results obtained in leukemia, sustain the combination of a pro-
differentiation agent with chemotherapy, suggesting the synergic action of 
BMP7v in combination with conventional drugs used in the management of CRC 
disease. BMP7v in combination with standard chemotherapy reduced CR-CSCs 
tumor growth in vivo as showed by strong reduction of tumor size, and by lower 
expression of CD133, CD166, beta-catenin, Lgr5 and Ki67, with a significant 
increase of CK20 compared to control, suggesting anti-proliferative and pro-
differentiative effects in vivo. 
Our findings confirm the rationale for combining a pro-differentiation agent with 
chemotherapy drugs, supporting the use of BMP7v in colorectal cancer patients. 
Since BMP7v treatment resulted in a notable necrotic effect, paraffin embedded 
xenografts sections were analyzed for CD31 and VEGFR2 expression. 
The histological examination showed a significant reduction of human CD31 and 
VEGFR2 expression following BMP7v treatment, but not BMP4 treatment. This 
anti-angiogenetic effect was confirmed through an endothelial tube formation 
assay. These findings confirm a specific anti-angiogenic effect of BMP7v in 
colorectal cancer xenografts 
BMP7v also showed a significant anti-tumor activity in xenografts refractory to 
chemotherapy, revealing a strong necrotic effect and a greater efficacy compared 
to combined treatment in tumor xenografts previously treated with standard 
chemotherapy. 
These results also support the possible use of BMP7v in colorectal cancer, 
providing evidence for its efficacy also in pre-treated patients.  
Concluding, the clinical benefit obtained by the combination of a 
prodifferentiative agent with chemotherapy led us to propose the combination of 
BMP7v with current standard chemotherapy regimens for CRC further supporting 
the usefulness of CSCs differentiation as a CRC therapy. 
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 2 
ABSTRACT 
 
Cancer stem cells (CSCs), characterized by high levels of ATP-binding cassette, 
anti-apoptotic molecules, active DNA-repair and slow replication capacities, 
surviving to conventional anti-cancer therapies, able to eradicate only the highly 
proliferating tumor cells, represent the elective target for new therapies. 
Colorectal CSCs (CR-CSCs) represent a powerful tool for preclinical validation 
of target therapies. In particular the elucidation of the mechanisms that govern 
stem cell survival and differentiation appears very essential for the identification 
of new molecular targets in cancer therapy. Among the molecules that govern 
these processes there are the Bone Morphogenetic Proteins (BMPs), members of 
the TGF-b superfamily. Here we propose that a BMP7 variant (BMP7v) have an 
important antitumoral and anti angiogenetic effect on CR-CSCs inducing a 
differentiation program and making these cells more sensitive to conventional 
chemotherapy drugs. BMP7v in vitro administration, activates the BMP signaling 
pathway in CR-CSCs, reducing the percentage of stem cell marker expression and 
enhancing epithelial colonic differentiation marker expression. BMP7v reduces 
self-renewal of CR-CSCs inducing their exit from quiescence and, reducing their 
typical mesenchymal trait, decreases their invasive and endothelial cord formation 
capacity. In vivo, BMP7v decreases tumor growth and stem cell marker 
expression, enhancing differentiation compared with control mice and in 
combination with CRC standard chemotherapy reduces tumor growth, inducing a 
differentiative and antiproliferative effect, associated with a strong anti-
angiogenic role. In addition, BMP7v as second-line of treatment also showed a  
significant anti-tumor activity in xenografts refractory to chemotherapy. Our data 
support the use of BMP7v as differentiative agent in combination with cytotoxic 
drugs for the treatment of CRC, and the use of BMP7v provides a potentially 
powerful and novel approach for the treatment of tumor disease. 
 
 
 
 
 
 
 
 
 
 
 
  
 3 
INTRODUCTION 
 
Colorectal cancer and stem cell theory 
The colorectal cancer (CRC) is one of the most common cancers in Western 
countries. It represent the third form of cancer for frequency and the second 
leading cause of cancer death due to the resistance to current clinical therapies in 
the world. (1). 
Nowadays, the most important approaches, for the managment of this complex 
pathology remain the prevention and the early diagnosis, although a large 
numbers of patients after surgery and adjuvant therapy still develop recurrences 
and metastasis, due to the acquisition of resistance to conventional therapy, such 
as chemo- and radio-therapy (2). 
The colorectal cancer represent a classic example of a multistep pathogenesis, 
characterized by the acquisition of aberrant function of a proto-oncogene or loss 
of function of a tumor suppressor gene (3). Many studies showed that at least 4–5 
mutations are necessary to generate an invasive carcinoma (4). Some of these 
mutations seem to follow a constant trend, within the same sequences, and they 
are shared by many patients affected by colon-rectal cancer, unlike, other different 
mutations are individuals and therefore necessary to determine the final phenotype 
of disease (5). Many evidences on colon cancer mutations derived from studies on 
hereditary forms, representing 5% to 10% of all colon cancer cases. In particular, 
Familial adenomatous polyposis (FAP) is an autosomal dominant CRC syndrome 
caused by a mutation in the APC (adenomatous polyposis coli) gene which 
characterizes multiple CRC (6-8). 
In 1990, Fearon and Volgestein proposed a genetic model of colorectal 
carcinogenesis based on the accumulation of genetic mutations that occur in 
sequence, defining a particular staging of tumor development (9).  
The main event which characterizes the onset of CRC is represented by 
mutations-inactivating the gene APC that lead to hyperproliferation of the normal 
intestinal epithelium with the formation of adenomas class I (early adenoma ). In 
fact, the APC mutations are reported as the initiating gatekeeper that regulate 
positively the Wnt pathway in patients with FAP (10). The key role of APC 
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protein is represented by the modulation the cytoplasmic levels of beta-catenin, a 
protein that migrating into the nucleus activates the transcription of genes 
involved in the regulation of proliferation, differentiation, migration and apoptosis 
(11).  
The progression from early adenoma towards the stage of intermediate adenoma 
is related to the acquisition of B-RAF and K-RAS mutations. These mutations, 
mutually exclusive, determine the constitutive activation of the Ras-Raf-MAPK 
protein signaling pathway.  
The loss of heterozygosis involving the chromosome 18q, the mutations in 
SMAD4 (Small Mother against DPP homolog 4), CDC4 (Cell Division Cycle 4) 
and DCC (Delected in Colorectal Cancer) or alternatively mismatch repair 
deficiency, P53, Bax and IGFR2 (insulin-like growth factor receptor 2) are 
involved in the transition to advanced adenoma (adenoma late) (4, 12, 13). 
Finally, a key event in the transition from advanced adenoma to carcinoma is 
represented by acquisition of mutations in one of the most important tumor 
suppressor genes, TP53. It is a powerful transcription factor, able to maintain the 
integrity of the genome through the regulation of the expression of more than 300 
genes involved in various cellular processes such as apoptosis, cell cycle arrest, 
senescence and DNA repair.  
The tumor suppressor gene TP53 is mutated in about 95 % of human cancers of 
various origins. Cancer cells that are non-functional TP53 have a substantial 
advantage in growth, since they can proliferate actively, even under conditions of 
stress or damage to the genome, developing resistance to apoptosis.  
Finally, the accumulation of additional mutations, many of which are still not 
known, induce the transformation in metastatic carcinoma (14). Fig.1. 
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Fig.1. Schematic representation of colorectal cancer multistep progression. (Di Franco S. et 
al., Encyclopedia of Molecular Cell Biology and Molecular Medicine, Wiley.) 
 
In the last decades the tumor biology has revolutionized the old view of 
tumourigenesis. CRC, as the other tumors, have long been consider as an 
exclusively genetic disorder. Nowadays, several studies showed that tumors are 
constitute by a highly heterogeneous population of tumor cells which differ in 
morphology, marker expression, proliferation capacity and tumorigenicity. To 
better describe the role of the different malignant cells within the same tumor, and 
to explain this morphological, proliferative and functional heterogeneity, two 
models have been proposed: the stochastic and hierarchical models. 
The first model, described by Nowell in 1976 (15) proposed that all cells within a 
tumor are biologically homogenous and able to regenerate the tumor (16). This 
model of tumorigenesis, in fact, describes the tumor formation as a process 
multistep due to the sequential accumulation of mutations in oncogenes and tumor 
suppressor genes. Accordingly, all cells within the same tumor are able to initiate 
a new tumors, but this theory does not consider the high cellular heterogeneity, 
the chemoresistance, the minimal residual disease and the tumor recurrence. In 
sum, tumors consist of a heterogeneous cell population that, acquiring new 
mutations, undergoes uncontrolled proliferation and invasivity. 
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Otherwise, the hierarchical model, considering all the factors intrinsic and 
extrinsic involved in defining cell behavior, such as, genomic instability, levels of 
transcription factors, signalling pathways, microenvironment and immune 
response, is based on the analysis of the high cell heterogeneity within the tumor 
in terms of features, surface markers expression, proliferation kinetics and tumor 
initiation capacity (17). 
This model suggest that only a subset of tumor cells within the tumor mass, called 
Cancer Initiating Cells or Cancer Stem Cells (CSCs), can initiate and sustain 
tumor growth (18). These cells possess the tumorigenic and self-renewal capacity, 
and the ability to differentiate in non-self renewing cells, that acquiring 
proliferative capacity, constitute the tumor bulk (19). Fig.2. 
 
 
 
 
 
 
 
Fig.2. Two general models of heterogeneity in solid cancer cells: a) stochastic and b) 
hierarchical models. (Reya T. et al. Stem cells, cancer, and cancer stem cells, Nature 2001) 
 
In the last years, novel insights in cancer research have suggested that the capacity 
to initiate and sustain tumor growth is a unique characteristic of this small subset 
of cancer cells with stemness properties within the tumor mass, called “cancer 
stem cells” (CSCs) or “tumor-initiating cells”, that have the capacity to propagate 
the tumor upon transplantation into immuno-compromised mice (19). 
CSCs are defined by their stem cell-like features that share with the normal stem 
cells that are characterized by self-renewal and pluripotent differentiation 
capacity. These cells are responsible to generate, through several cycles of 
division, progenitor cells which give rise to non-tumorigenic differentiated 
population that represent most part of the tumour mass. CSCs could derive either 
from self-renewing normal stem cells (SCs) that acquire epigenetic and genetic 
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changes required for tumorigenicity or from proliferative progenitor cells (PCs) 
that reprogramming themself acquire the self-renewal potential capacity (20). 
Emerging evidences suggest that CSCs isolated from a variety of tumors types 
retaining the tumorigenic capacity are responsible for the propagation, relapse and 
metastatic dissemination. CSCs can explain the phenomenon of the tumour 
chemoresistance in which several mutations confer to these cells drug-resistance, 
altered cell cycle checkpoints and impaired apoptosis machinery. For all these 
reasons, CSCs survive to conventional treatments giving often rise to minimal 
residual disease (MRD). Therefore to better understand the mechanisms that 
maintains stemness features and the subsequent characterization of CSCs could be 
crucial to develop new most appropriate anti tumor strategy approaches. 
Common signaling pathways, including Wnt, Notch and Sonic Hedgehog are 
involved in the regulation of normal and cancer stem cell. Many evidences 
underlining the importance of these cellular signalling showed as their 
deregulation plays an key role in the tumor development (21). Accordingly, 
several studies suggest the importance of self renewal pathways activation for 
CSCs maintainance (22). 
The CSCs theory has changed the conventional therapeutic approches, suggesting 
an alternative strategy targeted to these cellular subset. The CSCs are 
characterized by high resistance to conventional chemotherapeutic drugs that kill 
the rapidly proliferating cells sparing the slow dividing cells, through a particular 
upregulation of ATP-binding cassette transporters, active DNA-repair capaciy and 
overespression of antiapoptotic molecules (23, 24).  
Dick and collegues were the first to isolate and characterize CSCs from acute 
myeloid leukemia (AML) in blood and bone marrow. In particular they isolated a 
sub-population of CD34+CD38- from patients affected by AML, and they 
demonstrated that only this cellular subset was able to form colonies in vitro 
experiments. They also analized that only this subset was able to reproduce the 
parental tumor phenotype, when inoculated into immunodeficient mice (25, 26). 
Using a similar procedure many research groups identified a large number of 
tumor stem cell from a different solid tumor type. In particular, the first CSCs 
obtained from a solid tumor were a cellular subset CD44+CD24- isolated from 
breast cancer by Al Hajj et coll. (16). Subsequently, were isolate several different 
 8 
CSCs tumoral type: brain (27), colon (28-30), head and neck (31), pancreas (32, 
33), melanoma (34), mesenchymal (35), hepatic (36), lung (37), prostate (38), and 
ovarian (39) tumors. 
 
Colon crypts and stem cells 
Although the SCs and CSCs characterization has been long studied, several 
molecules have been identified as a putative stemness markers, up to now, none of 
the markers studied seems to be exhaustive. Scientific evidences underline the 
importance to use different combinations of these markers in order to obtain a cell 
population enriched in stem cells. 
The adult intestinal epithelium presents a particular structure ordered into crypts 
and villi, organized with a hierarchical organization, composed by three different 
cell types: the colonocytes or columnar cell, the mucin-secreting goblet cells and 
the endocrine cells, originated from a colonic stem cell. These stem cell, located at 
the base of the crypt are surrounded by mesenchymal cells that form the stem 
niche, in which the stem cell, displaying stemness features, can generate through 
asymmetric division, a cell identical to itself , and a transit cell. The transit cell 
(rapidly dividing cells) proliferating and differentiating, migrates along the crypt, 
representing all the intestinal lineage (40-45). According to this theory these stem 
cells are responsible for the high turn over rate of the colonic epithelial cells (46-
48). 
This particular and complex structure of the colon crypts has made particular 
difficult the studies about the mechanisms of crypt formation from a single stem 
cell. The first study regarding the stem cell position in the colon was conducted by 
Chang et al. using 3H-thymidine injection, and recently it was confirmed using 
bromodeoxyuridine DNA-labeling dye (49, 50). 
Two different models have been proposed regarding the positioning of the stem 
cells: the “stem cell zone” model and the “ +4 position” model. According to the 
first model, the colon stem cell reside at the very bottom of the crypts. Unlike, the 
second model describes that the stem cells are located at the +4 position above the 
Paneth cells at the base of the crypts (51). 
Although the absence of a specific colonic stem cell markers makes their 
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identification and positioning very difficult, the colonic stem cell can be 
characterized by two main features: self-renewal and differentiation capacity. 
Stem cells may undergo asymmetric division, but they can also generate two 
identical stem cells via symmetric division that acquiring a diffentiated phenotype 
regenerate the colon tissue. Then, in the first case, it is possible to obtain a lineage 
expansion, but in the other case, a lineage extinction, because the differentiated 
progeny undergo to senescence. 
Accordingly with the CSCs theory it is widely accepted that the stem cells are 
responsible for the origine of the cancer. Their slow division cycle, allow them to 
accumulate several mutations over time up to define them CSCs (52-54).  
Different molecules have been proposed as a stemness markers: Musashi 1(Msi1), 
EphB receptors, Bmi 1, Lgr5. 
Msi1, an RNA binding protein, widely studied in Drosophila Melanogaster, seems 
to be involved in the asymmetric division that regulate the neural development, 
also in mammals. In human and murine small intestine it is located at the base of 
the crypts. Its silencing determines tumor growth arrest by Notch inhibition and 
p21 upregulation, proteins involved in stemness mainteinance (55-57).  
EphB2 receptor is tyrosine kinase receptor, belonging to the family of Wnt target 
gene, it is expressed in a decresing gradient from the crypt base toward the 
differentiated cell compartment (58). This expression along the crypts seems 
regulate the migration and proliferation of intestinal epithelium; mutants in their 
ligands, or mutant forms of these receptors involve in intestinal 
compartimentalization defects. Underlining their important role in the intestinal 
positioning of the different cell types along the crypts. (59). 
Bmi1, a repressor of Polycomb group, is involved in hematopoietic, breast and 
neural self renewal. In the small intestine it is expressed near to the bottom of the 
crypts (60, 61). 
Lgr5 is a G protein coupled receptor, belonging to the family of Wnt target gene. 
Its expression in a single cells is able to regenerate a crypt-like structure in vitro 
constituted by all cell type of colonic epithelium (62). This and other markers as 
have been associated with CSCs phenotype. 
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CR-CSCs identification, isolation and expansion 
The existence of colorectal CSCs (CR-CSCs), have been showed, for the first 
time, thanks to the detection of a new stemness markers, the transmembrane 
glycoprotein, CD133. This surface expressed polypeptide is associated with self 
renewal and tumor initiating cells, this protein was first associated as a marker for 
hematopoietic stem cells and progenitor cells, and successively used in other 
tumor type: (63): brain (27), prostate, hepatocellular and colon tumors (28-30, 64, 
65). 
Recently two indipendent groups have revealed that only CD133+ subset of tumor 
cells within a colon carcinoma, is able to initiate a tumor outgrowth (28-30). 
Accordingly, it has been showed that a small group of CD133+ cells is able to 
serially reproduce the original human tumor phenotype, rather than an high 
number of CD133- cells that fail to generate xenograft tumors in immuno-
compromised mice. In line with these data, only the tumorigenic CD133+ cells 
population generated crypt-like structures in vitro under differentiation condition 
on matrigel (65). In addiction, these cells during differentiation in vitro and in 
vivo acquire a typical epithelial colonic marker, CK20, reducing at the same time 
the CD133 stem cell marker.  
Accordingly, many clinical reports suggest CD133 as an indipendent prognostic 
marker and its combination with a nuclear localization of beta catenin is 
associated with a reduced patients survival (66-69).  
In sum, several research groups demonstrated that only the CD133+ cellular sub-
population, within a colon carcinoma, is able to initiate and sustain tumor growth 
(68-70).  
Moreover, mantaining the CD133+ cells with the same conditions of 
neurospheres, these cells were expansed for long term without loss their ability to 
reproduce human original tumor phenotype, underlining the self renewal and 
tumor initiation capacity of these sub population (28, 29).  
O’Brien and collegues, in order to evaluate whether all the CD133+ cells are CSCs 
or whether these subpopulation contains also more differentiated progenitors, 
through serial dilution assays, showed that the CD133+ subpopulation not only 
contains cancer initiating cells.  
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Accordingly, recent studies analyzed a new sub-group, contained in CD133+ cells, 
the CD44+/Epcam High/CD166+ stem like cells. Dalerba et al., (30) demonstrated 
that the CD44+/Epcam high cell subpopulation injected in NOD-SCID mice, is 
able to reproduce a tumor xenograft phenotypically similar to parental one.  
In a similar way, Du’s et al., (70) showed that also CD44 could be considered a 
putative marker, able to discriminate a subpopulation capable to growth in vitro as 
spheres and in vivo producing xenografts, resembling the parental human tumor. 
The role of CD133 as a marker of stem cell has long been debated, in particular, 
after the Shmelkov et al. publication, in which it was shown that CD133 is 
expressed ubiquitously in both undifferentiated and mature colonic cells (71). 
While the lack of CD133 expression is only found in the stromal and 
inflammatory cell compartment.  
Differently, Zhu et al. analizing the role of Prominin1, the mouse analogue of 
CD133, in adult colon tissue, showed that the Prominin1+ cells marking the adult 
colon stem cells, represent the target of tumoral trasformation. (72). 
On the bases of these conflicting data, it became clear that the use of a single 
marker is not adequate for a correct CSCs identification and isolation, to identify 
the subpopulation of CSCs, it would be more appropriate to use a panel of 
markers and to standardize protocols that can validate the use of a new marker. 
For all these reasons, several surface molecules have been proposed to mark colon 
CSCs, such as CD133, LGR5, CD44 and CD166. (73, 28-30).  
Recently, it has been demostrated that undifferentiated tumorigenic CRC cells 
could be expanded as tumor spheres in vitro using a serum-free medium 
containing EGF and basic FGF (74). The tumor spheres, infact, contain an 
heterogeneous cell population expressing a variable percentage of CD133, 
CD166, CD44, CD29, CD24 and nuclear beta-catenin. More recently ALDH1, a 
detoxifying enzyme, has been proposed as a specific marker able to identify, 
isolate and track human normal and CSCs during CRC development (75, 76). 
This marker is expressed by the CD44+ or CD133+ cells, located at the base of 
normal crypts. After sorting the ALDH1 high cells, injected subcutaneously in 
NOD SCID mice, generate tumor xenografts (76).  
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The isolation of CSCs is based essentially on two different approaches: the use of 
a culture medium serum-free that maintain stemness-selective conditions, 
originally developed for neural stem cell culture (77) or the direct selection by 
magnetic sorting or FACS technology for putative markers distinctively expressed 
by a cell subpopulation. On the bases of these procedures there is a common step 
in which the surgical excisions of solid tumours are processed by mechanical 
and/or enzymatic digestion to obtain a single-cell suspension. This freshly digest 
obtained is constitute by an cells heterogeneous mixture of the original tissue. In 
order to selectively obtain CSCs, the digest is cultured into ultra-low-adhesion 
flasks in a specific serum free medium, supplemented with growth factors such as 
basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). These 
conditions allow the undifferentiated tumour cells, stem and transit amplifying 
cells, to survive and slowly proliferate, while the differentiated cells die through 
anoikis. Sphere-forming cells are maintained in culture by dissociation and re-
plating as single cells, and retain the tumorigenic potential when injected into 
immunocompromised mice, reproducing the same morphological and antigenic 
features of the original tumour, data showed by histological examination of 
xenografts generated from spheres. This tumorigenic capacity is serially 
maintained, and the xenografts can be digested and the cells obtained can be 
indefinitely propagate under stemness conditions, maintaining the stem like 
features as well as the capacity to reform tumors. As previously described, a 
single clonogenic CD133+ cell, contained in CRC spheres is able to reproduce the 
original tumor, including the CSC compartment and the differentiated progeny. 
Alternatively, the second procedure, involves the selection of putative stem cell 
marker from the whole digest, by the use of monoclonal antibody directly or 
indirectly conjugated with magnetic beads. This sorting allow a double positive 
and negative selection, separating labelled and unlabelled cells, but this procedure 
permit only a single-marker selection. Another alternative method is represented 
by FACS sorting, which allows sorting of different populations with multi 
parameter analysis, testing contemporary several antibodies conjugated to 
different fluorochromes. 
Moreover the sorted cells can be also cultivated in stem cell conditions and also 
injected into immunocompromised mice to directly test the tumorigenic capacity 
(74).  
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Intestinal Niche 
Fibroblast, endothelium, inflammatory cells, cytokines and growth factors 
secreted by these cells, constitute the intestinal niche and are involved in CSCs 
maintenance at the base of colon crypts. They finely regulate the balance between 
self-renewal and differentiation (78-80). Indeed the pluripotency of colon SCs is 
strongly controlled by microenvironment that plays a crucial role ensuring a fine 
equilibrium between important pathways, such as PTEN-PI3K-Akt (81, 82), Bone 
Morphogenetic Protein (BMP) (83), Notch (84) and Sonic hedgehog (Shh) (85). 
In particular the intestinal sub-epithelial myofibroblast (ISEMFs) surrounding the 
normal colon stem cells, regulate this balance secreting hepatocyte growth factor 
(HGF) for maintenance of stem cell in the intestinal niche. The presence of 
ISEMFs or HGF, as demonstrated by Vermulen et al., restore the stem cell 
phenotype, inducing a cellular de-differentiation (80). 
The colon crypt unit represented in figure 3, shows a particular cellular 
distribution in which at the basis of the crypt are located the mesenchymal cells 
(ISEMFs) and their secreted factors responsible for the stem cell niche 
maintenance, while along the villux apex, where are located several Wnt 
inhibitors, in order to reduce the stemness features it is possible to identify a 
progressive cellular differentiation. The pathways mentioned above, are involved 
in self renewal and are de-regulated both in normal and CSCs (21, 22).  
One of the most studied pathway envolved in CSCs progression is represented by 
the Wnt signalling. 
The Wnt signalling in the basis of the crypts promotes nuclear beta catenin 
accumulation, which activate the transcription of several genes involved in cell 
cycle regulation and proliferation. Beta catenin also induces the expression of 
EphB1-2, which regulate stemness, cell migration and differentiation (86-88). 
The distribution of Wnt pathway members, results particularly regulated. Wnt 
ligands are predominantly expressed at the basis of the crypts and are reduced 
along the crypt where more differentiated cells reside, and where are most express 
the Wnt inhibitors factors (88-90). 
In addiction to Wnt pathway, BMP, Notch and Shh pathways regulate the niche 
homeostasis. 
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BMP proteins are TGF-beta superfamily members that through binding to 
receptors BMPR1A, BMPR1B and BMPR2 can trigger different biological 
processes in CSCs (91). 
The activation of this pathway promotes the phosphorylation of Smad1, 5 and 8 
that in association with SMAD 4 translocate into the nucleus and in cooperation 
with other transcriptor factors regulate the target genes expression (92, 93). 
Recent data have demonstrated that the BMPs promote terminal differentiation 
and apoptosis (94). Kosinsky et al., analyzed the distribution of the different 
factors along the crypt: the cells at the apex of the crypt express high levels of 
BMPs, while at the basis of the crypt, their levels are reduced, but the levels of 
BMPs antagonist, produced by myofibroblasts, contribute to the maintenance of 
stemness (95, 83). 
Notch pathway is envolved in intestinal SCs fate and includes four different trans-
membrane receptors (Notch1 to Notch4). The binding of five different ligands 
(Jagged-1, -2, Delta-like 1, 2 and 4) induces the release of the Notch intracellular 
domain that translocates into the nucleus where it forms a complex with DNA-
binding proteins activating the target genes transcription involved in epithelial cell 
fate determination (96). Recent reports showed its key role in intestinal 
homeostasis and neoplastic transformation. Moreover, the expression of Notch 
intracellular domain blocks cell differentiation, inducing expansion of immature 
progenitors (97, 84). Defects in Notch pathway were observed in colon cancer 
stem cells (CCSCs), using an antibody anti DLL4 (an important Notch pathway’s 
component) to directly inhibit human colon cancer xenograft growth.  
Finally, Sonic Hedgehog pathway regulate the gut organogenesis, binding to its 
receptor Patched (PTCH), allowing the release of a G-coupled protein 
Smoothened (Smo), which with the GLI transcriptors factors migrate into the 
nucleus inducing target gene activation (85) 
In several cancers, such as leukemia, pancreas, stomach, prostate, breast, 
glioblastoma and colon cancer were found many alterations in the Hedgehog 
pathway (98-103). 
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In conclusion, the aberrant alteration of these pathways involved in self-renewal 
of the intestinal stem cells could be the driving force that promote colon cancer. 
(104)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. Graphic representation of a colon crypt. (Di Franco S. et al. Colon Cancer Stem Cells: 
Bench-to-Bedside-New Therapeutical Approaches in Clinical Oncology for Disease Breakdown. 
Cancers 2011).  
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Clinical implication of CR-CSCs and BMPs as alternative therapeutic 
strategy  
The CSCs theory, in colorectal cancer, has exciting clinical implications, 
confirming that the therapy failure and relapses are due to the CSCs resistance. 
Indeed, CSCs, retaining the stemness features, such as quiescence, self-renewal 
ability and multidrug resistance, represent the population intrinsically 
refractoriness to conventional therapies developed to eradicate the rapidly 
dividing cells that constitute the majority of the non stem cell component within 
the tumor.  
Nowadays, patients with metastatic CRC are treated with two useful protocols 
FOLFOX (Folinic acid/Fluorouracil and Oxaliplatin) and FOLFIRI (FOLFOX 
plus vitamin B and irinotecan). Neoadjuvant chemotherapy for these patients, is 
represented by anti-angiogenic drugs as the Bevacizumab, a humanized 
monoclonal antibody that targets the vascular endothelial growth factor (VEGF), 
which plays an inportant role as angiogenic factor in primary and metastatic 
human CRC (105, 106). Another neo-adjuvant drug is Cetuximab, also known as 
Erbitux, a monoclonal antibody that inhibits the epidermal growth factor receptor 
(EGFR), indicated for the treatment of EGFR expressing patients affected by 
KRAS wild-type metastatic colorectal cancer, alone or in combination with 
FOLFIRI (107). 
The future of diagnostics and treatments of tumor disease should aim to eliminate, 
not only the terminally differentiated component of the tumor bulk, but, it should 
be focused, in particular, to the subpopulation of cancer stem cells that represent 
the driving force for the tumor expansion (19). In order to evaluate the CR-CSCs 
role in the therapy response, recurrence and metastasis, a recent work showed that 
the subpopulation of CD133+ CR-CSCs results more resistant to both 
conventional chemotherapeutic drugs, and innovative therapies, compared to 
epithelial cells that constitute the majority cell population within the tumor (65, 
74). 
These recent findings support the idea that tumor-initiating cells are highly 
resistant to cytotoxic cancer therapies, underlining the importance of their role in 
colorectal tumors refractoriness and recurrence also many years after the 
"successful" treatment of primary tumour.  
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The CSCs contribute to the poor therapeutic sensitivity through many 
mechanisms, such as preferential activation of DNA damage checkpoint, high 
levels expression of ABC transporters and anti-apoptotic molecules, slow 
replication capacity and other aberrant molecular mechanisms that destroy the 
normal balance between proliferation and survival or cell death (23). 
In addition the CSCs refractoriness is finely regulated by microenvironmental 
soluble molecules that are involved in many different sectors of tumor 
development, regulating the growth, migration, and differentiation of all cellular 
components into both the tumor mass and in the microenvironment. 
The possibility to isolate and study CSCs represents a revolutionary approach in 
cancer research and these cells represent the elective target for new therapies, 
endowed to high and selective toxicity towards the specific tumor with reduced 
toxicity for normal cells. 
An alternative therapeutic strategy seems to be represented by selectively target of 
CSCs pathways . 
Recent reports have demonstrated that the autocrine production of IL-4 by cancer 
cells from breast, thyroid, colon, and lung acts as negative regulator of apoptosis, 
conferring resistance to death receptors and chemotherapy-induced cell death 
(108). Moreover IL-4 seem to be involved in stimulation of activated B-cell, in T-
cell proliferation and the differentiation of CD4+ T-cells into Th2 cells (109). The 
use of anti–IL-4 neutralizing antibody or IL-4 receptor α antagonist, on CR-CSCs, 
inhibiting IL-4 signaling transduction pathway, sensitizes these cells to 
chemotherapeutic agents through down-regulation of anti-apoptotic proteins, such 
as cFLIP, Bcl-xL, and PED. Moreover, the combined use of IL-4 antibodies plus 
5-fluorouracil or oxaliplatin also reduces xenografts tumor growth (65). 
Concluding, recent studies have evaluated that the CR-CSCs CD133+, are 
protected by apoptosis phenomenon through the up-regulation of IL-4 (110). 
Another important approach could be represented by cancer immunotherapy. 
Although the cancer cells are less immunogenic than their normal counterpart, the 
immune system could plays a crucial role in order to effectively and safely 
increase antitumor responses recognizing and eliminating them (111). Although, 
these cells do not express MHC molecules, making tumor cells resistant to αβ T 
cell-mediated cytotoxicity, recently, it has been demonstrated that a subpopulation 
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of T cells, the γδ T cells, show potent MHC-unrestricted lytic activity versus 
different tumor cells in vitro, suggesting their potential employment in anticancer 
therapy. γδ T cells have been isolated and identified from tumor infiltrating 
lymphocytes in different cancer types. 
The development of targeted therapies for colorectal cancer requires new 
therapeutic regiments that aims to eliminate the self-renewal compartment of 
tumor mass by targeting stemness features owned by CR-CSCs, making this 
population more sensitive to conventional drugs. This is the main goal that the 
differentiation therapy aims to achieve. 
The therapy based on the induction of differentiation is aimed to affects the self 
renewal ability of CSCs, and could represent an alternative way to inhibit tumour 
growth. 
Among the molecules that govern stem cell survival and differentiation, the Bone 
Morphogenetic Proteins (BMPs), a subgroup of TGF-b superfamily members, 
play an important role in the regulation of colon stem cell features and contribute 
to the network of the signals that define the intestinal stem cell niche modulating 
the equilibrium between proliferation and differentiation signalling pathways 
(112-114)  
These proteins and their intracellular signaling components have been conserved 
in Drosophila and Caenorhabditis elegans and they were originally isolated from 
bone. The major contribution to their isolation and characterization was made by 
Sampath and Reddi (115). 
BMPs are synthesized as large precursor proteins in the cytoplasm where they are 
proteolytically processed in a mature proteins (116). The mature BMP molecules 
are characterized by a cysteine knot with the seven conserved cysteine domains. 
The dimeric form is active as a homodimer or heterodimer with a molecular 
weight of about 30-38 kDa. 
BMPs bind to two different transmembrane serine/threonine kinase receptors, 
type I (BMPRI) and type II (BMPRII). Type I receptors include activin receptor 
type IA (ActRIA or ALK2) and BMP receptors type IA and IB (BMPRIA or 
ALK3; BMPRIB or ALK6), while type II receptors are represent by BMP 
receptor type II (BMPRII), activin receptor type IIA and IIB (ActRIIA and 
ActRIIB) (117, 118). After the formation of heteromeric complexes, type II 
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receptor phosphorylates the type I receptor (119) and the signalling pathway is 
then activated through Smad and non-Smad mechanism (117, 119). In addition to 
the Smad pathway, indeed, the BMPs activate an alternative pathway, which 
includes p38 and ERK MAP kinases (120). When Smad 1,5,8 protein (R-Smad) 
are phyosphorylated by the type I receptors, they can interact with co-Smad 
(Smad4) and after translocate into the nucleus in order to initiate the transcription 
of BMPs response genes (121). 
The Inhibitory Smads, Smad 6/7, inhibits BMP signaling (122), indeed, BMPs 
activation is tightly regulated by the presence or the absence of antagonists and 
inhibitors such as Gremlin, Chordin and Noggin (83). BMP antagonists are 
soluble factors that control BMPs signaling with various degrees of affinity and 
specifity, binding the BMPs, preventing the functional receptor/ligand interaction: 
twisted gastrulation (TSG), chordin and noggin and the DAN-family of inhibitors. 
BMPs are involved in the earliest stage of development, and play a key role in the 
normal intestinal development, growth and morphogenesis. Their signalling act to 
mediator between epithelial and mesenchymal stroma interaction necessary for 
the correct intestinal homeostasis (123).  
During the human and mouse intestine development, BMP7 and BMP6 were 
found, respectively, on the intestinal epithelium and smooth muscle cells (124, 
125). Moreover, the high expression of BMP2 and BMP4 in the mesenchymal site 
drive the villus formation (126). In particular many reports showed that the BMPs 
pathway is functional in all three tissue layers of the gastro-intestinal tract, to 
allow the reciprocal correct interaction. Mice overexpressing the BMP-antagonist 
noggin, undergo to abnormal villus morphogenesis, associated with stromal and 
epithelial hyperplasia, ectopic crypt formation, due to low levels of BMPRIA and 
pSmad1/5/8 (123).  
All these results suggest that human gastro-intestinal and chronic intestinal 
diseases, could be associated with defects in the BMPs signaling pathway (113).  
Hardwick et al., have demonstrated that the mature colonocytes at the epithelial 
surface of normal human and mouse colon, express BMP2, the BMP receptors (Ia, 
Ib, II), phosphorylated Smad1 and Smad4 (112). Stroma and crypt epithelium of 
the adult mouse intestine show an high expression of BMPRIA and BMP2 (123, 
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127). While, Haramis et al showed that BMP4 is expressed in stromal cells and 
mesenchimal cells surrounding the crypt and glands of the intestine (127, 113). 
The BMPs pathway components result highly expressed in colon tops while the 
BMP antagonists gremlin 1, gremlin 2 and chordin-like 1, produced by 
myofibroblasts and smooth muscle cells, are located in basal colon crypts.  
Juvenile polyposis (JP), is an autosomal dominant hamartomatous polyposis 
syndrome in which germline mutations of two members of the BMPs pathway are 
involved. The patients, having mutations or deletions in SMAD4 and BMPR1A 
genes (128-130) are predisposed to upper gastrointestinal and colorectal cancer, in 
almost half of the cases. JP patients, with SMAD4 mutations, showed a significant 
prevalence of gastric polyposis (131). SMAD4, known as a tumor suppressor gene 
in pancreatic and colon cancer, in JP acts as a susceptibility gene, a “gatekeeper“, 
its loss of function results in polyp formation in which an important role is played 
by stromal inflammatory response regulating epithelial tumorigenesis (132). 
Homozygous SMAD4 knockout mice, develop polyps, with thickened intestinal 
mucosa and loss of villus architecture showing plasma cell infiltrates into the 
stroma, while mice with conditional SMAD4 deletion in the intestinal epithelial 
cells did not develop intestinal tumors (133). Although, JP patients with a 
germline SMAD4 mutation, showed biallelic inactivation of SMAD4 in both the 
epithelium and stroma, suggesting a common clonal origin (134). 
Another gastro-intestinal disease, Familial adenomatous polyposis (FAP), is an 
autosomal dominant syndrome, characterized by hundreads of adenomatous 
colorectal polyps due to a deletion in the adenomatous polyposis coli (APC) gene, 
localized on chromosome 5q21. APC gene, as above mentioned, is involved in 
ubiquitine-mediated degradation of beta catenin, regulating Wnt signalling and its 
functional defects leads to uncontrolled cell proliferation (135). In FAP patients, 
an higher expression of Wnt signaling molecules, results in BMPs signaling 
downregulation, differently, in intestinal homeostasis, the BMPs inhibit the 
effects of Wnt-pathway to regulate the intestinal stem cell proliferation and 
repression of polyps formation (113, 127). Many results showed that 
heterozygous APC mutant mice, with higher expression of the BMPs antagonist 
Gremlin 1 and lower BMP2 and BMP4 expression develop severe polyposis and 
faster rate of tumor growth (136). Accordingly, human FAP tissue specimens in 
 21 
dysplatic mycroadenomas epithelium do not maintain BMP2 expression (112). 
The association of these genetic disorders, with the BMPs signaling pathway, was 
confirmed by experiments on transgenic mice, overexpressing the BMP 
antagonist, noggin or mice with conditional inactivation of BMPRIA. These mice 
showed an increased formation of intestinal polyps (113, 127). Moreover, 
conditional inactivation of BMPRII in stroma, led to multiple hamartomatous 
polyp appearance. (137, 138). 
These findings indicate that altered BMPs expression plays an important role in 
aberrant cellular proliferation and tumorigenesis in the human intestine. During 
the last decade, extensive researches were conducted to explain the factors 
involved in the initiation and progression of colorectal cancers in particular, 
BMPs and their signaling pathway have been specially studied. (139, 140). 
Many different groups have demonstrated that several BMPs are suppressive for 
colorectal cancer cells growth (112, 141, 142). Back et al. showed that BMP2 
exerts growth suppression by increasing p21WAF1 protein levels, and not its 
transcription, modulating RAS-ERK pathway (143). 
Moreover, the loss of BMP signaling seems to be correlated to tumor progression, 
indeed, the BMPs expression, is lost from late adenoma to early carcinoma. 
Abnormal CSCs proliferation in CRCs, is due to an abnormal activation of Wnt 
signalling pathway and BMPs signalling inhibition, that promote nuclear beta-
catenin accumulation through PTEN downregulation and iperactivation of PI3K-
Akt pathway (113). Confirming that the BMPs pathway alteration leads to pre-
cancerous lesions (138). 
The TGF-β signalling inactivation plays a key role in CRC development (144), 
indeed, it has been reported that the loss of BMPRII and SMAD4 is frequently 
deleted also in sporadic CRC and that BMPs pathway is inactivated in the 
majority of colorectal tumors (145, 146). This is strongly supported by a 
transgenic mice model in which the inactivation of the BMPs pathway leads to 
polyps formation and up-regulation of Wnt signalling (127). 
Considering BMPs’ role in regulating SCs differentiation and inducing apoptosis 
and differentiation program, it is possible to suppose that CSCs treatment with 
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these molecules could inducing differentiation, make these cells more sensitive to 
conventional chemotherapies.  
Some preliminary studies have been performed on both CSCs of glioblastoma 
(GBM) and CRCs.  
Interestingly, it has been recently demonstrated that in human glioblastoma BMP-
BMPR signalling, controls the activity of normal brain stem cells, and inhibits 
glioblastoma stem like cells (GSLCs) (147). It has been also demonstrated that 
BMP2, BMP4 and BMP7 treatment inhibits sphere forming capacity and induces 
differentiation of CD133+ cells; reducing in vivo glioblastoma tumor growth (147-
149). 
Recently, it has been demonstrated that the treatment of CR-CSCs with BMP4 
induces in vitro differentiation and reduces their tumorigenic potential, sensitizing 
these cells to conventional chemotherapic drugs reducing the tumor size and 
inducing complete long-term regression of colon CSC-derived xenograft tumors 
(94). 
Given the regulatory effect of BMPs on neural stem cells, their progenitors and 
GSLCs, recently, Tate et al. have demonstrated that BMP7 variant (BMP7v) acts 
on proliferation, differentiation, angiogenesis, and in vivo tumorigenicity of 
GSLCs isolated from surgical specimens of primary GBM. In particular, BMP7v, 
decreases proliferation of GSLCs, inducing their differentiation into neuronal- and 
astrocyte cellular phenotypes, and inhibites angiogenic endothelial cord 
formation. These results were confirmed by in vivo analysis of subcutaneous or 
orthotopic tumor models. Their data suggest that BMP7v therapy, directed against 
CSCs and angiogenesis, represents a potentially powerful therapeutic option that 
may improve the poor outcome of conventional treatments (150). 
The current therapeutics strategy target and kill differentiated tumor cells that 
constitute the tumor bulk, failing to affect the rare cancer stem-like cell 
population.  
These data suggest the use BMPs, as alternative therapy, to induce the 
differentiation of CSCs and to make them more sensitive to conventional 
chemotherapy. Since the differentiated tumor cells are more sensitive to 
conventional cancer therapies, therapy differentiative represents another possible 
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therapeutic strategy to inhibit tumor growth by inducing the differentiation of 
CSCs, making them more susceptible to the action of chemotherapeutic agents.  
The induction of CSCs differentiation provides a potentially powerful and novel 
approach to the treatment of cancer disease. 
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AIMS 
 
The high mortality rate of colorectal cancer (CRC) is mainly due to the inefficacy 
of standard treatments to cure the metastatic disease. The recurrence and relapse 
characteristic of this kind of cancer suggest that the only one curative therapy 
could be represented by targeting the subpopulations of tumor cells with 
tumorigenic potential, the so-called, cancer stem cells (CSCs) (151). Several 
studies report that radio-chemotherapy, directed against differentiated cells, 
forming the bulk of tumor cell population, are unable to eradicate the tumorigenic 
and metastagenic population, without obtaining a long-term clinical remission. 
Accordingly, the induction of differentiation, affecting the self-renewal ability of 
CSCs, represents an alternative way to inhibit tumor growth and to sensitize CSCs 
to conventional chemotherapy. The treatment of CSCs towards terminally 
differentiation represent an intriguing concept for future therapy. On the basis of 
these data my project proposed to investigate the role of a stable BMP7 variant 
(BMP7v) on CR-CSCs in order to make these cells more sensitive to conventional 
chemotherapy drugs and to develop a new treatment protocol easily tested in 
preclinical models to design a future appropriate clinical trials. 
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MATERIALS AND METHODS 
 
Tissue collection, isolation and culture of cancer cells 
Human CRC tissues were obtained from patients undergoing to CR resection, in 
accordance with the ethical standards of the institutional committee. Normal colon 
mucosa was obtained from the histologically uninvolved resection. Histological 
diagnosis was based on the morphological microscopic features of carcinoma 
cells, determining the histological type and grade.  
Surgical specimens were intensively washed in PBS solution containing 
antibiotics and incubated overnight in DMEM/F12 (GIBCO) containing penicillin 
(500 U/ml, GIBCO), streptomycin (500 µg/ml, GIBCO) and amphotericin B (1.25 
µg/ml, GIBCO) in order to avoid contaminations. Tumor tissues were 
mechanically and enzymatically digested. Enzymatic dissociation was performed 
using collagenase and hyaluronidase in DMEM for 1 hour at 37° C. Dissociated 
CRC cells were then cultured in presence of serum-free medium supplemented 
with epidermal growth factor (20 ng/mL) and basic fibroblast growth factor (10 
ng/mL, both from Sigma-Aldrich, St. Louis, MO 63103, USA) in non-adherent 
conditions, in ultralow adhesion flasks (Corning, Lowell, MA), to promote the 
growth of CSCs as spheres. These culture conditions allow the selection and 
propagation of tumour spheres, containing immature tumour cells, while non 
malignant or differentiated cells are negatively selected. To achieve in vitro 
differentiation of CSCs, dissociated sphere cells were cultured in DMEM-high 
glucose supplemented with 10% FBS in adherent conditions. These cells were 
conventionally indicated as sphere-derived adherent cells (SDACs). All cell 
cultures were carried out at 37°C in a 5% CO2 humidified incubator. Magnetic 
cell separation was performed on tumour cell populations obtained from 
enzymatic dissociation of CRC specimens using microbeads conjugated with 
CD133/1 (AC133, mouse IgG1, cell isolation kit, Miltenyi). After magnetic 
sorting, viability was assessed using trypan blue exclusion. Quality of sorting was 
verified by flow cytometry with an antibody against CD133/2 (293C3-PE, mouse 
IgG1, Miltenyi) on both CD133+ and CD133− depleted cell population.  
Cell death was evaluated by orange acridine/ethidium bromide staining or by 
CellTiter Glo Assay Kit (Promega) accordingly to manufacturer’s instruction. 
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BMP7v used for this work was produced by Eli Lilly and Company. The 
pharmaceutical development of BMP7v represented the major limitation with its 
suboptimal solubility at neutral pH. Mutations into the N terminus of the BMP7v 
prodomain were introduced to enhance the cleavage of prodomain and mature 
domain. Five point mutations were addicted onto the surface of the mature 
domain, through a random mutagenesis approach, to create a molecule that 
retained the same signaling properties of wild-type BMP7 but had greater 
expression and enhanced biophysical properties such as solubility and stability. 
BMP7v material can be made available to researchers upon request to the Lilly 
authors (152).  
In order to detect the proportion of differentiated and undifferentiated cells, 
dissociated spheres were cultured in stem cell medium in presence of BMP7v 
(100ng/ml) up to 18 days. At different time points, the adherent cells were 
harvested with trypsin and mixed with floating cells. The cell mixture was then 
cytospun and stained for CK20 and CD133. 
To evaluate BMP7v role in differentiation in vitro, the spheres were dissociated 
into single cells and cultured in the presence of BMP7v (100ng/ml) for 48 hours 
or 90 minutes in order to evaluate the p-Smad 1, 5, 8 nuclear traslocation. 
 
Histochemistry and Immunohistochemistry /Immunofluorescence 
Histochemical and immunohistochemical/immunofluorescence analyses were 
performed on 5 µm paraffin-embedded sections of human normal colon and CRC 
tissues or subcutaneous tumor xenografts and cytospuns of freshly sorted cells and 
spheres cells exposed to BMP7v  
The following antibodies were used: BMP7 (164311, mouse IgG2B; R&D 
system), CD133 (AC133, mouse IgGb; Miltenyi), BMPRIA, (87933, mouse 
IgG2b; R&D Systems), BMPR1B (88614, mouse IgG2a; R&D Systems), BMPR2 
(73805, mouse IgG2b; R&D Systems), pSmad 1,5,8 (rabbit polyclonal; CST), 
cytokeratin 20 (Ks20.8, mouse IgGa; Dako Cytomation), p21(#2947, Rabbit IgG; 
CST), E-cadherin (rabbit polyclonal; CST), Vimentin (#39325, Rabbit; CST), 
Beta-catenin (H102, rabbit polyclonal; Santa Cruz Biotechnology), CD166 
(MOG/07, Mouse Monoclonal Antibody; Leica), Lgr5 (RB 14211, Rabbit Ig; 
ABGENT) Ki67 (MIB-1, mouse IgG1; Dako Cytomation), CD31 (clone JC70A, 
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mouse IgG1Kappa; Dako ytomation), VEGFR2 (goat IgG; R&D System) or 
isotype-matched controls at appropriate dilutions. 
For immunohistochemistry (IHC) the dewaxed slides were heated for 1 min at 
450 W and 5 min at 100 W in a microwave oven in 0.1M citrate buffer pH 6.0 or 
pH 9.0 only for KI67 staining. For cytoplasmatic epitopes detection, samples were 
permeabilized with 0.1% TritonX-100 in PBS for 10 min sections and after the 
slides were incubated with Tris-buffered saline (TBS) containing 10% AB human 
serum to block unspeciﬁc binding. After elimination of excess serum the sections 
were exposed overnight at 4°C to speciﬁc Abs against BMP7, CD133, CD166, 
Beta-catenin, Lgr5, Ki67, CK20, CD31, VEGFR2 or isotype-matched controls at 
appropriate dilutions. Following exposure to primary Abs, sections were treated 
with biotinylated anti-mouse- rabbit and anti goat immunoglobulins, washed in 
PBS and then incubated with streptavidin peroxidase (LSAB 2 Kit; Dako 
Cytomation or Vectastain kit; Vector). Stainings were detected using 3-amino-9-
ethylcarbazole (AEC) chromogen. Counterstain of nuclei was performed using 
aqueous hematoxylin (Sigma). 
For hematoxylin and eosin (H&E) staining, dewaxed sections were stained in 
Hematoxylin (Sigma) for 1 minutes, washed in water and then exposed for 30 
seconds to eosin (Sigma). Stained sections were dehydrated and mounted with 
syntetic resin. 
For Azan Mallory, sections were stained with azocarmine G (Sigma) for 1 hour 
and with 5% of phosphovolframic acid for an additional hour. Then, sections were 
stained with aniline blue/orange G (Sigma) and mounted in synthetic resin. 
All IHC images were analyzed with Imaging Analyzer Software 
Apoptotic events were determined by TUNEL labeling  using In Situ Cell Death 
Detection, AP Kit (Boehringer Mannheim) (roche). DNA strand breaks were 
detected by 5-bromo-4-chloro-3-indolyl-phosphate (BCIP, Dako Cytomation) 
substrate.  
Immunofluorescence stainings were performed on 5-µm-thick embedded sections 
of human CRC tissues, on cytospun freshly sorted cells, spheres cells allowed to 
differentiate in 10% FBS or after exposure to BMP7v. Cells were fixed in 2% 
PFA for 20 min at 37°C. For cytoplasmatic epitopes detection, samples were 
permeabilized with 0.1% TritonX-100 in PBS for 10 min, blocked with 3% BSA 
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for 30 min and exposed overnight at 4°C to antibodies against BMP7, CD133, 
BMPRIA, BMPRIB and BMPRII, p-SMAD1,5,8, CK20, p21, E-cadherin, 
Vimentin and beta-catenin or isotype-matched controls at appropriate dilutions. 
Then, cells were treated with FITC or Rhodamine anti-mouse or anti-rabbit 
antibodies (Molecular Probes, Inc.) plus RNase (200 ng/ml, Sigma). Nuclei were 
counterstained using Toto-3 iodide (642/660, Molecular Probes). Confocal 
analysis was used to acquire fluorescence stainings. 
 
RNA isolation and Real-time PCR 
Total RNA from cell pellet was obtained using the Rneasy Mini Kit (Qiagen 
GmbH), the residual amounts of DNA remaining was removed using the RNase-
Free DNase according to manufacturer’s instructions. The yield of the extracted 
RNA was determined by measuring the optical density at 260 nm by Nanodrop 
ND-1000 (Nanodrop, Wilmington, DE). 
1 µg of total RNA was retro-transcribed using High-Capacity cDNA Archive Kit 
(Applied Biosystems) according to manufacturer’s instructions. PCR 
amplification and detection of the PCR amplified gene products were performed 
with the SYBR Green PCR master mix (SuperArray Bioscience, Frederick, MD) 
All amplification reactions were done in triplicate, and the relative quantitation of 
gene expression was calculated using the comparative Ct method (ΔΔCt). Levels 
of mRNA expression were expressed after normalization with endogenous 
control, GAPDH. For SYBR green chemistry, the following primers were 
purchased from MWG: BMPR1A forward primer 5' GTC ATA CGA AGA TAT 
GCG TGA GGT TGT 3', BMPR1A reverse primer 5' ATG CTG TGA GTC TGG 
AGG CTG GAT T 3, BMPR1B forward primer 5' AAG GCT CAG ATT TTC 
AGT GTC GGG A 3', BMPR1B reverse primer 5' GGA GGC AGT GTA GGG 
TGT AGG TCT TTA TT 3', BMPR2 forward primer 5' GTG ACT GGG TAA 
GCT CTT GCC GTC T 3', BMPR2 reverse primer 5' GCA GGT TTA TAA TGA 
TCT CCT CGT GGT 3', GAPDH forward primer 5' GCT TCG CTC TCT GCT 
CCT CCT GT 3', GAPDH reverse primer 5' TAC GAC CAA ATC CGT TGA 
CTC CG 3'.  
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Flow cytometry 
Flow cytometry was performed on freshly purified colon cancer cells after 
magnetic CD45+ cells depletion, SDAC and dissociated sphere cells untreated and 
treated with BMP7v. Cell preparations were fixed in 2% paraformaldehyde for 10 
min at 37°C and permeabilized by 0.1% Triton-X 100 for 10 min at 4°C to detect 
cytoplasmatic epitopes. Cells were washed twice with 0.5% bovine serum 
albumin (BSA, Sigma) in PBS and exposed to antibodies against CD133/2 
(293C3-PE, mouse IgG2b, Miltenyi), CD133/1 (AC133, mouse IgG2b, Miltenyi), 
CK20 (Ks20.8, mouse IgG2a, DAKO Cytomation). Samples were then incubated 
with FITC-conjugated anti-mouse or anti-rabbit antibodies (Molecular Probes). 
Cells were subjected to flow cytometry analysis using a FACSCalibur cytometer 
and Cell Quest Software (Becton Dickinson). Only cells with staining intensities 
above the maximal level of isotype-matched controls were defined as positive 
cells. 
Cell cycle analysis was performed on dissociated sphere cells untreated and 
treated with BMP7v for 48 hours and SDACs. The cells were washed in PBS and 
fixed in ice-cold 70% ethanol at 4°C overnight and then incubated with PBS 
containing propidium iodide (50 µg/ml, Sigma), sodium citrate (3.8 Mm, Sigma) 
and RNase (10 µg/ml, Sigma) at 37°C for 30 minutes. Samples were analyzed 
using a flow cytometer (BD Biosciences). 
PKH26 (Sigma) staining was performed, according to manufacturer’s 
instructions, on dissociated sphere cells, untreated and treated with BMP7v 
(100ng/ml) for 48 hours, up to 14 days, at different time points these cells were 
harvested for the FACS analysis,  
 
Protein isolation and immunoblotting 
Cell pellets were re-suspended in ice-cold NP40 lysis buffer [50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl, 1 mM EGTA, and 1% NP40] containing proteases and 
phosphatases inhibitors and fractioned on SDS-polyacrylamide gels and blotted 
on nitrocellulose membranes. Membranes were blocked for 1 hour with nonfat 
dry milk in TBS containing 0.05% Tween 20 and successively incubated with 
antibodies specific against PTEN (17A, mouse IgMk, Neomarkers), AKT (rabbit 
polyclonal, CST), p-AKT (Ser 473, rabbit polyclonal, CST), GSK3ß (rabbit 
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polyclonal, CST), p-GSK3ß (Ser9, rabbit polyclonal, CST) and beta-actin 
(JLA20, mouse IgM, Calbiochem) used as loading control. Membranes were then 
washed, incubated for 1 hour with horseradish peroxidase-conjugated anti-mouse, 
anti-rabbit or anti-goat immunoglobulins (Amersham Biosciences) and developed 
with a chemiluminescence detection system (SuperSignal West Pico/Dura 
Extended duration Substrate, Pierce Biotechnology). Densitometric analysis of 
protein expression level was performed by Vision Works LS (UVP). Results were 
expressed as protein/beta-actin OD ratio. 
 
Clonogenic and colony forming assays 
Dissociated sphere cells untreated and treated with BMP7v for 48 hours were 
plated in presence of stem cell medium, on ultra-low-adhesion 96-well plates at a 
concentration of a single cell per well. Wells containing either none or more than 
one cell were excluded for this analysis, but these valors was used to calculate the 
cancer stem cell frequency, with ELDA software. 
Colony forming was performed on dissociated sphere cells untreated and treated 
with BMP7v, 5FU+Oxaliplatin alone or in combination. Cells were plated on 
Agarose Sea Plague Agar (Invitrogen), and maintained up to 21 days at 37°C in 
presence of 5% CO2.  The colonies were stained with 10% Cristal Violet. 
 
Invasion assay 
Cell migration capacity was assessed using growth factor–depleted matrigel–
coated (BD Biosciences) transwell insert. Dissociated sphere cells (2x103) 
untreated and treated with BMP7v 100ng/ml for 48 hours were plated into 
matrigel-coated transwell of 8 µm pore size (Corning). Supernatant of NIH-3T3 
cells, cultured in stem cell medium was used as chemoattractant in the transwell 
lower part. Migration was observed  and counted microscopically up to 96 hours. 
 
RT2 ProfilerTM PCR Array.  
The RT2 Profiler PCR array was assessed for genes related to Wnt targets (PAHS-
243ZR-12; SuperArray Bioscience). It was used to simultaneously examine the 
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mRNA levels of 89 genes closely associated with Wnt pathway, including five 
"housekeeping genes" in 96-well plates following the manufacturer's protocol. 
Cycle threshold values were calculated for all the genes present on the array and 
normalized using the average of 5 housekeeping genes (ACTB, B2M, HPRT1, 
RPLP0 and GAPDH). RT2 Profiler PCR Array Data Analysis was represented by 
clustergrams based on Pearson’s Correlation of 2^ (ΔCt). 
 
Animals and tumor model 
Mice were obtained from Charles River Laboratories (Milan, Italy) and 
maintained according to institutional guidelines of the University of Palermo 
animal care and committee. Dissociated CRC sphere cells (5x105) were implanted 
subcutaneously (s.c.) with matrigel GF reduced (BD Biosciences) at a 1:1 ratio in 
a total volume of 100 µL into the flank of five-to-six week old NOD-SCID mice. 
Tumor mass size was calculated according to the formula: (π/6) x larger diameter 
x (smaller diameter)2. When tumors were palpable the mice were treated three 
times a week by intraperitoneal injection of BMP7v for three weeks at different 
concentrations: 50, 5, 0.5 and 0.05µg/kg, and PBS as control, in order to test the 
efficacy dose.  
Then the other set of mice were treated three times a week for three weeks by 
intraperitoneal injection (IP) of PBS, as control, BMP7v (50µg/kg) alone or in 
combination with 5FU and Oxaliplatin. (5-FU: 15 mg/kg/day for 2 days a week 
for 3 weeks; and Oxa: 0.25 mg/kg once a week for 3 weeks). 
Histological examination, analysis of differentiation, incidence of cell death and 
mitotic index were determined on tumor xenografts using AC133, CK20, TUNEL 
and Ki67 staining. 
To test the BMP7v activity as second line treatment, when the tumor xenografts 
obtained as previous described, were palpable, the standard adjuvant treatment, 
Oxaliplatin (0.25 mg/kg once a week for 3 weeks) and 5-FU (15 mg/kg/day for 2 
days a week for 3 weeks) was performed intraperitoneally on eight mice for 
group. After this first line of treatment with 5FU plus Oxaliplatin alone for two 
weeks when tumor re-growth, the follow IP treatments were performed: PBS, 
5FU+Oxaliplatin, BMP7v and BMP7v+5FU+Oxaliplatin, in a standard protocol 
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for three weeks. The tumor xenografts obtained after 13 weeks from injection 
were used for histological examination. 
 
Endothelial tube formation assay 
The effects of BMP7v on in vitro endothelial tube formation were evaluate using 
HUVEC, obtained from Lonza (Clonetics, Verviers, Belgium) and grown in 
endothelial growth medium (EGM) according to supplier’s information. HUVEC, 
pretreated with BMP4 (2nM R&D System) and BMP7v (100ng/ml) for 24, 48, 72 
hours, were plated (70,000 cells/well) in Matrigel-coated 24 well plate (BD 
Bioscience), and incubated up to 5 hrs at 37°C. Endothelial tube formation, 
evaluated by phase-contrast microscopy, was photographed at different time 
points and the cables length was measured manually with the IMAGE-J software. 
 
Statistical analysis 
Data were expressed as mean ± standard deviation of the mean. 
Immunohistochemical  scores were calculated from the positivity observed on 
paraffin-embedded engrafted tumor tissues counted by two independent 
observers.  
Statistical significance was determined by Analysis of Variance (one-way or two-
way) with Bonferroni post-test. Results were considered significant when p values 
were less than 0.05. * indicates P<0.05, ** indicate P<0.01, ***  indicate 
P<0.001. 
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RESULTS 
 
BMP7 is widely expressed in colo-rectal cancer tissue but not in colo-rectal 
cancer stem cells 
Human colo-rectal cancer (CRC) specimens were provided by the Surgical 
Department of Policlinico “Paolo Giaccone”, Palermo.  
These tumors and their normal counterpart (obtained from the edge of the resected 
specimen) were analysed for BMP7 expression with immunohistochemistry: CRC 
specimens widely expressed BMP7, compared to their normal counterpart 
(Fig.4A).  
Expression of this cytokine was also analysed with immunofluorescence (IF) on 
paraffin embedded cancer tissue: BMP7 was localized along the upper part of the 
crypt, with the exception of the base of the crypt where stem cells reside (Fig.4B). 
These findings prompted us to investigate whether there is differential expression 
of BMP7 between cancer stem cells (CSCs) and their differentiated counterpart 
using our in vitro models, i.e. sphere cells and sphere-derived adherent cells 
(SDACs), respectively. While SDACs displayed high levels of BMP7 expression, 
sphere cells showed very low positivity.  
We also analyzed BMP7 expression in CR-CSCs sorted for CD133 positivity, a 
known CSC marker: IF analysis showed that BMP7 is exclusively expressed by 
CD133- cells (Fig.4C-D). 
All in vitro experiments shown in this report were conducted in three different cell 
lines. The images are from one cell line, but are representative of results obtained 
for all three cell lines. 
These data suggest a correlation between BMP7 expression and differentiation of 
CRC cells, and therefore a possible role in CSCs differentiation.  
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Fig.4. CD133+ CR-CSCs do not express BMP7. A) Immunohistochemical analysis for BMP7 on 
normal and tumoral colon paraffin-embedded sections. Nuclei are revealed by hematoxylin 
staining (blue). B) Confocal microscopy analysis of BMP7 (green) on CRC paraffin-embedded 
tissue. Nuclei were counterstained with Toto-3 (blue). C) Representative images of 
immunofluorescence analysis of BMP7 (green) in sphere cells (Spheres) and SDACs. Nuclei were 
counterstained with Toto-3 (blue). D) Representative images of immunofluorescence analysis of 
BMP7 (green) on CD133- and CD133+ CRC cells sorted from the sample as in C. Nuclei were 
counterstained by Toto-3 (blue). 
 
 
 
BMP7v in vitro administration activates the BMP signaling pathway in CR-
CSCs. 
To evaluate the possible use of BMP7v as a differentiative agent of CSCs, we 
analysed the expression of BMP receptors through real-time PCR and IF analysis.  
Both CRC sphere cells and SDACs expressed BMPR1A, BMPR1B and BMPR2 
(Fig.5A). 
  
Positive control Normal colon Colon cancer
Spheres SDACs
BMP7 CD133 BMP7
CD133 - CD133 +
A 
B 
C D 
Colon cancer
BMP7
 35 
In order to verify the BMPRs functionality in CR-CSCs, we evaluated p-SMAD1-
5-8 localization with IF after treatment with BMP7v (100ng/ml): activation of the 
BMP7 pathway was confirmed by the prevalent p-Smad1,5,8 nuclear 
translocation following treatment (Fig.5B-C).  
Western blot analysis of downstream targets to the BMP7 pathway are consistent 
with these findings (Fig.5D). 
These results indicate that exogenous addition of BMP7v can activate the 
canonical BMP signaling pathway in CR-CSCs.  
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Fig.5. BMP7v administration activates the canonical signaling pathway in CR-CSCs. A) 
Relative quantification of BMPR1A, BMPR1B, and BMPR2 mRNA expression levels in sphere 
cells (Spheres) and SDACs. B) Representative images of immunofluorescence analysis of 
BMPR1A, BMPR1B, and BMPR2 (green) in sphere cells and SDACs. Nuclei were counterstained 
with Toto-3 (blue). C) Representative images of confocal microscopy analysis of pSmad1,5,8 
(green) in sphere cells, untreated or treated with BMP7v for 90 minutes or 48 hours. Nuclei were 
stained with Toto-3 (blue). D) Densitometric analyses of protein expression levels of AKT, p-
AKT, PTEN , GSK3β and p- GSK3β in sphere cells, untreated or exposed to BMP7v for 48 hours, 
and SDACs. Loading control was assessed by β-actin.  
 
 
 
BMP7v induces in vitro differentiation in CR-CSCs and reduces the 
percentage of CD133+ cells 
To evaluate the role of BMP7v in inducing differentiation, we tested whether 
sphere cells could be forced to differentiate upon exposure to the morphogenetic 
factor. CRC sphere cells were cultured in the presence of BMP7v or 10% FBS. 
BMP7v alone induced a rapid differentiation of CR-CSCs, evaluated by plastic 
adherence and acquisition of the typical differentiated appearance, i.e. large size 
and polygonal shape (Fig.6A).  
Accordingly, BMP7v treatment reduced the percentage of CD133+ and increased 
CK20 expression in CR-CSCs (Fig.6B-C). 
Reduction of the CD133+ cells following 48 hours of BMP7v treatment was also 
confirmed by flow cytometry (Fig.6D). 
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Fig.6. BMP7v promotes in vitro differentiation of CR-CSCs. A) Representative images of 
phase-contrast microscopy of dissociated sphere cells, untreated or treated with BMP7v up to 18 
days. B) Percentage of CK20+ sphere cells, untreated or treated with BMP7v up to 18 days. C) 
Percentage of CD133+ sphere cells, untreated or treated with BMP7v. D) Representative flow 
cytometry profile of CD133 expression in sphere cells, untreated or treated with BMP7v for 48 
hours. 
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BMP7v reduces self-renewal of CR-CSCs  
To evaluate the effect of BMP7v treatment on CR-CSCs self renewal capacity, we 
performed the in vitro colony forming assay. BMP7v, given for 48 hours, reduced 
the CR-CSCs sphere forming capacity.  
We also tested the effect of combining BMP7v to standard chemotherapy 
(5FU+Oxa): this treatment resulted in a more significant reduction of clonogenic 
capacity compared to chemotherapy alone in CR-CSCs. 
To further test the CR-CSC sensibility to BMP7v, one week after the first step of 
treatment, the cells were re-treated: this treatment reduced the colony forming 
efficiency even more drastically (Fig.7A-B).  
As p21 seems to be a key regulator of CR-CSC self renewal, we also evaluated its 
cellular localization with IF: BMP7v treatment induces depletion of nuclear p21, 
confirming the induction of cell cycle progression, with consequent cancer stem 
cell clone exhaustion (Fig.7C). 
We showed that BMP7v treatment not only reduces CR-CSCs self-renewal but 
also potentiates the effect of standard chemotherapy. 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
PB
S
C
he
m
o
B
M
P7v B
M
P7
v 
B
M
P7v+C
hem
o 
2
ndLine
1s
t L
in
e
0
10
20
30
40
50
Co
lo
ny
 fo
rm
in
g 
ef
fic
ie
nc
y 
%
1st Line 2nd Line
A B 
 39 
 
 
 
 
 
 
 
Fig.7. BMP7v reduces self renewal of CR-CSCs. A) Representative colony forming assay of 
sphere cells, untreated or treated with 5FU+Oxaliplatin (chemo), BMP7v alone (BMP7v), 
BMP7v+5FU+Oxaliplatin (BMP7v+chemo), for 48 hours; these treatments were performed once 
as a 1st line or repeated after one week as a 2nd line of treatment. B) Percentage of colony forming 
efficiency in sphere cells, untreated or treated as in A. C) Representative images of confocal 
microscopy analysis of p21 (green) in sphere cells, untreated and treated with BMP7v for 48 hrs. 
Nuclei were stained with Toto-3 (blue). 
 
 
BMP7v induces CR-CSCs to exit from quiescence 
We then evaluated the effect of BMP7v on cell cycle distribution. FACS analysis 
revealed that 48 hours of BMP7v treatment, unlike to BMP4, induced a 
significant increase in the percentage of cells in the G2/M phase, with a reduction 
of cells in G0/G1.  
Interestingly, the BMP7v induced cell cycle distribution in sphere cells was 
similar to the baseline SDACs profile (Fig.8A-B). 
To evaluate the effect of BMP7v on proliferation of CR-CSCs, we performed 
PKH26 staining: treatment induced a reduction of PKH26 high cells, confirming 
the induction of proliferation in a time dependent manner (Fig.8C-D). 
These data suggest that, in addition to differentiation induction, BMP7v treatment 
displays an unexpected proliferative effect.  
This cytokine drives different cell subpopulations present in sphere cultures to 
exit from the quiescent state, characteristic of stem cells, thus making them more 
sensitive to standard chemotherapies. 
Taken together, these in vitro results indicate that BMP7v treatment is able to 
reduce stemness of CR-CSCs.  
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Fig.8. BMP7v induces CR-CSCs to exit from quiescence. A) Representative cell-cycle profile 
of sphere cells, untreated or treated with BMP7v for 48 hours, and SDACs. B) Cell-cycle 
distribution of sphere cells treated as in A. C) Representative PKH-26 profile of sphere cells, 
untreated or treated with BMP7v up to 14 days. D) Percentage of PKH-26 high cells treated as in 
C. 
 
 
BMP7v reduces the mesenchymal CR-CSCs traits 
Given the link between CSCs, epithelial-mesenchymal transition (EMT) and 
metastasis, we tested the effect of BMP7v treatment on CR-CSCs invasive 
capacity, using a transwell migration assay: BMP7v drastically reduces CR-CSC 
motility and invasiveness (Fig.9A).  
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We then analysed expression of EMT markers, such as E-caderin, Vimentin and 
beta-catenin: BMP7v suppressed the mesenchymal trait, inducing E-cadherin 
expression and cytoplasmic localization of beta-catenin, while silencing Vimentin 
(Fig.9B). 
Given the role of the Wnt pathway in EMT, a Wnt signaling trascriptional profile 
was performed on CR-CSCs after 48 hours of BMP7v treatment to verify its 
action on regulation of Wnt targets: results revealed a strong regulation of Wnt 
targets involved in stemness and migration.  
BMP7v induced upregulation of Wnt inhibitors such as SFRP2 and Axin2, 
associated with down regulation of stem cell markers, such as SOX2 e Nanog. In 
addition, the treatment reduced expression of migration regulator genes, such as 
Met and MMP2 and 7 (Fig.9C).  
These results confirm the induction of differentiation via the Wnt pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.9. BMP7v reduces the mesenchymal CR-CSCs traits. A) Invasion assay of sphere cells, 
untreated or treated with BMP7v for 48 hours at different time points up to 96 hrs. B) 
Representative images of confocal microscopy analysis of E-cadherin, Vimentin and Beta-catenin 
(green) in sphere cells, untreated or treated as in A. Nuclei were stained with Toto-3 (blue). C) 
Wnt target card clustergram on sphere cells untreated or treated as in A. 
 
  
M
ed
iu
m
E-cadherin
B
M
P7
v
Vimentin Beta-cateninB 
C 
 43 
BMP7v in combination with standard chemotherapy reduces CR-CSCs 
tumor growth in vivo 
To evaluate the effects of BMP7v on CR-CSCs tumor growth in vivo, different 
concentrations were administered intraperitoneally (IP) three times a week.  
Three to four weeks after subcutaneous injection of sphere cells, palpable tumors 
were observed in immuno-compromised mice. BMP7v treatment was started at 
different doses listed below: 50, 5, 0.5 and 0.05µg/kg. 
The results showed a reduction in tumor size and a notable necrotic effect 
confirmed by Azan Mallory staining on paraffin embedded xenografts sections: 
these effects were more pronounced in the 50µg/kg group (Fig.10A-C). 
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Based on these findings, we decided to use 50µg/kg in combination with standard 
chemotherapy, to evaluate whether BMP7v could enhance its cytotoxic effect in 
vivo.  
Tumors were obtained injecting Smad4-wt, Smad4-null and Smad4-null PI3K/CA 
sphere cells. They were then exposed to Oxaliplatin plus 5-FU alone or in 
combination with intraperitoneal injection of PBS or BMP7v. 
Combined treatment resulted in a considerable reduction of tumor growth in 
Smad4-wt and Smad4-null, while it was less effective in Smad4 null harboring 
PI3KCA mutation.  
BMP7v alone gave a more pronounced growth delay than standard chemotherapy 
(Fig.10D). 
Histological analysis of xenografts treated with BMP7v plus chemotherapy 
showed an high percentage of dying cells and large areas of fibrosis, highlighted 
by TUNEL staining (Fig.10E). 
BMP7v plus chemotherapy treated tumors showed lower expression of CD133, 
CD166, β-catenin, Lgr5 and Ki67, with a significant increase of CK20 compared 
to control, suggesting anti-proliferative and pro-differentiative effects in vivo 
(Fig.10E-L).  
Our findings confirm the rationale for combining a pro-differentiation agent with 
chemotherapy drugs, supporting the use of BMP7v in colorectal cancer patients. 
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Fig.10. BMP7v in combination with standard chemotherapy reduces CR-CSCs tumor 
growth in vivo. A) Size of subcutaneous tumors following injection of sphere cells. When tumor 
xenografts were palpable immuno-compromised mice were treated intraperitoneally three times a 
week with BMP7v (50, 5, 0.5 or 0.05 ug/Kg) or with PBS as control. B) Percentage of necrosis 
evaluated on paraffin-embedded sections of xenografts, untreated or treated as in A. C) 
Representative Azan-Mallory staining on paraffin embebbed xenografts untreated (PBS) or treated 
as in A. D) Size of subcutaneous CRC xenografts derived from injection of sphere cells. Mice 
were untreated (PBS) or treated intraperitoneally with BMP7v (50ug/Kg), 5-FU plus Oxaliplatin 
alone or in combination with BMP7v. The arrows indicate the starting point of treatment. Data 
were obtained on three different cell lines .E) Immunohistochemical analysis of CD133 and 
TUNEL (dark blue) revealed by AEC (red) on paraffin-embedded sections of xenografts obtained 
as in D. Nuclei are revealed by hematoxylin staining (blue). Arrowheads indicate TUNEL positive 
cells. F) Percentage of CD133+ cells evaluated on paraffin-embedded sections of tumors, untreated 
(PBS) or treated as in D. G) Percentage of TUNEL positive cells evaluated on paraffin-embedded 
sections of tumors untreated (PBS) or treated as in D. H) Immunohistochemical analysis of 
CD166, beta-catenin and Lgr5 revealed by AEC (red) on paraffin-embedded sections of xenografts 
obtained as in D. Nuclei are revealed by hematoxylin staining (blue). Arrowheads indicate CD166, 
beta-catenin and Lgr5 positive cells. I) Immunohistochemical analysis of Ki67 revealed by AEC 
(red) on paraffin-embedded sections of xenografts obtained as in D. Nuclei are revealed by 
hematoxylin staining (blue). Arrowheads indicate Ki67 positive cells. (upper: low magnification; 
lower: high magnification) J) Percentage of Ki67 positive cells evaluated on paraffin-embedded 
sections of tumors untreated (PBS) or treated as in D. K) Immunohistochemical analysis of CK20 
revealed by AEC (red) on paraffin-embedded sections of xenografts obtained as in D. Nuclei are 
revealed by hematoxylin staining (blue). (upper: low magnification; lower: high magnification) L) 
Percentage of CK20 positive cells evaluated on paraffin-embedded sections of tumors, untreated 
(PBS) or treated as in D. 
 
 
BMP7v has a strong anti-angiogenic effect in vivo 
Since BMP7v treatment resulted in a considerable growth delay associated with a 
potent necrotic effect, we investigated further its anti-angiogenic potential. 
Xenografts were exposed to BMP7v or BMP4, another member of the BMP 
family with an anti-tumour activity.  
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Histological examination showed a significant reduction of human CD31 and 
VEGFR2 expression following BMP7v, but not BMP4 treatment (Fig.11A-C). 
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We also performed an endothelial tube formation assay using endothelial cells 
from the umbilical vein (HUVEC): BMP7v affected the ability to form vessels 
after 48 hrs of treatment, while this was not observed for BMP4 (Fig.11D-F). 
These findings confirm a specific anti-angiogenic effect of BMP7v in colorectal 
cancer xenografts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11. BMP7v has a strong anti-angiogenic effect. A) Immunohistochemical analysis of CD31 
and VEGFR2 revealed by AEC (red) on paraffin-embedded section of xenografts obtained after 
PBS or BMP7v treatment (50ug/Kg). Nuclei are revealed by hematoxylin staining (blue). B) 
Percentages of CD31 and VEGFR2 expression evaluated on paraffin embedded sections of tumors 
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treated as in A. C) Immunohistochemical analysis of CD31 and VEGFR2 revealed by AEC (red) 
on paraffin-embedded section of xenografts obtained after intra-tumoral injection of PBS or BMP4 
loaded beads. Nuclei are revealed by hematoxylin staining (blue). D) Representative images of 
phase-contrast microscopy of endothelial tube formation assay. Huvec cells, untreated (EGM 
medium as control) or pretreated with BMP7v (100ng/ml) at different time points. E) Measure 
(pxl) of total tube length obtained with Huvec treated as in D. F) Representative images of phase-
contrast microscopy of endothelial tube formation assay. Huvec cells untreated (EGM medium as 
control) or pretreated with BMP4 (2nM) and BMP7v (100ng/ml) at different time points.  
 
 
BMP7v as second-line treatment shows significant anti-tumor activity in 
xenografts refractory to chemotherapy 
To test the activity of BMP7v as second line treatment, first line treatment with 
5FU plus Oxaliplatin was administrated for two weeks. After tumour re-growth, 
mice were treated with: PBS, 5FU+Oxaliplatin, BMP7v or 
BMP7v+5FU+Oxaliplatin, for three weeks. BMP7v alone showed greater efficacy 
compared to combined treatment in tumor xenografts previously treated with 
standard chemotherapy (Fig.12A). 
Hystological examination of xenografts, obtained 13 weeks after injection, 
revealed a strong necrotic effect. This was also confirmed with Azan Mallory 
staining (Fig.12B-C). 
These results further support the possible use of BMP7v in colorectal cancer, 
providing evidence for its efficacy in pre-treated patients. 
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Fig.12. BMP7v shows an anti tumor activity as second line treatment in xenografts 
refractory to chemotherapy. A) Size of subcutaneous CRC xenografts derived from injection of 
sphere cells. Mice were untreated (PBS) or treated intraperitoneally with 5-FU+Oxaliplatin for two 
weeks. After tumor re-growth mice were treated with PBS, BMP7v (50ug/Kg), 5-FU+Oxaliplatin 
alone or combination. B) H&E staining of paraffin-embedded sections of xenografts obtained as in 
A. C) Percentage of necrosis evaluated on paraffin-embedded sections of xenografts untreated 
(PBS) or treated as in A.  
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DISCUSSION AND CONCLUSIONS 
 
Current therapies mostly hit the differentiated cells, sparing the tumorigenic 
population which is responsible for the tumor relapse. Although clinical protocols 
are traditionally directed against the bulk of tumor cell population, increasing 
evidence suggests that curative therapies can be established only by targeting the 
subpopulations of tumor cells with tumorigenic potential. Several reports indicate 
that chemotherapy is more active on differentiated cells and generally ineffective 
against the tumorigenic population. In fact, traditional debulking agents often fail 
to produce long-term clinical remission and tumor relapses as a result of the 
inability to target cancer initiating cells (151). 
The induction of differentiation affecting the self-renewal ability of CSCs 
represents an alternative way to inhibit tumor growth and to sensitize CSCs to 
conventional chemotherapy drugs.  
According to recent publications, the tumor-initiating cells have stem like 
characteristics such as abilities of self-renewal, differentiation and invasion. 
Several research groups have identified tumorigenic populations with stem-like 
features in CRC (28-30, 73, 76, 80). These cellular subpopulation is able to 
promote tumor growth and is considered as an optimal cellular target to obtain 
effective therapies.  
Many reports suggest that the balance between self-renewal and differentiation in 
normal stem cells results deregulated in CR-CSCs. 
Indeed, the activation of Wnt signaling plays a key role in maintaining the normal 
stem cell population in the gut and promoting self-renewal of CR-CSCs (153-156) 
but also the cytokines, released in the microenvironment, contribute significantly 
to maintain the undifferentiated status and clonogenic activity of the tumorigenic 
cells (157). 
Thus, the differentiation therapy could represent a considerable therapeutic option 
for the treatment of colon cancer, inhibiting CSCs self-renewal ability and 
eradicating the tumor-driving cell population. Although this approach does not 
directly kill the cancer cells, it could make the conventional therapies more 
effective in the eradication of the tumor bulk.  
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For years retinoic acid has been used in the treatment and differentiation of 
promyelocytic leukemia, thus validating this concept (158). The pro-
differentiative effect of Bone Morphogenetic Protein 4 (BMP4) has been already 
proposed as a therapeutic option for human glioblastoma and colorectal cancer 
(147, 158-160) 
Moreover these treatments enhanced the antitumor activity of chemotherapeutic 
drugs, whose concomitant administration is able to induce a complete therapeutic 
response, also after treatment interruption. Thus supporting the combined use of 
differentiative and cytotoxic agents for cancer therapy. Accordingly, the induction 
of differentiation, affecting the self-renewal ability of CSCs, represents an 
alternative way to inhibit tumor growth and to sensitize CSCs to conventional 
chemotherapy.  
On the basis of these data, this work proposed to investigate the role of a stable 
BMP7 variant (BMP7v) on CSCs purified from CRC sample, in order to make 
these cells more sensitive to conventional chemotherapy drugs and to develop a 
new treatment protocol easily tested in preclinical models to design a future 
appropriate clinical trials. 
This study identifies, the use of BMP7v, as new potential therapeutic approach 
that activates CRC differentiation program. As previously described, the pro-
differentiation activity of BMPs, is perfectly detectable in normal gut in which 
these molecules are expressed following a decreasing gradient from the intestine 
lumen up to the crypt, thus limiting the stem cell expansion at the bottom of the 
crypts promoting the intestinal epithelial cell differentiation along the upper part 
of the crypts (113, 114).  
The present data show that all CRC specimens analysed, widely express BMP7, 
compared to their normal counterpart and its expression is limited to the 
differentiated progeny of CRC epithelial cells, which constitute the major 
population of the tumor mass. Here we demonstrated that BMP7 is localized 
along the upper part of the crypt, with the exception of the base of the crypt where 
stem cells reside. On the contrary, its expression is undetectable in the CD133+ 
CR-CSCs fraction. BMP7 results exclusively expressed by CD133- cells or in 
their differentiated counterpart, the sphere-derived adherent cells (SDACs). 
Although both CRC sphere cells and SDACs express BMPR1A, BMPR1B and 
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BMPR2. These results suggest a correlation between BMP7 expression and 
differentiation of CRC cells, and therefore a possible role in CSCs differentiation.  
The activation of the BMP signalling pathway was confirmed by the prevalent p-
Smad1,5,8 nuclear translocation following BMP7v treatment, as confirmed by 
analysis of downstream protein targets. Accordingly, BMP7v treatment increased 
PTEN levels inhibiting PI3K/AKT survival pathway confirming its differentiative 
role on CR-CSCs (161). 
BMP7v treatment induced a rapid differentiation of CR-CSCs, morphologically 
evaluated by plastic adherence and acquisition of the typical differentiated 
phenotype, into large and polygonal colonic cells. Consequently, this treatment on 
CR-CSCs reduced the percentage of CD133+ subpopulation increasing the CK20 
expression, a typical markers of epithelial colonic differentiation. 
BMP7v, also reduce the sphere forming capacity, and maintain this capacity also 
after a first step of treatment, showing that this second treatment reduces the 
colony forming efficiency even more drastically. Moreover BMP7v not only 
decreases CR-CSCs self-renewal but also potentiates the effect of standard 
chemotherapy. 
Taken together, these in vitro results indicate that this cytokine drives the different 
cell subpopulations present in sphere cultures to exit from the quiescent state, 
characteristic of stem cells, thus making them more sensitive to standard 
chemotherapies, as showed by cell cycle analysis. The BMP7v treatment in fact 
increased the percentage of cells in the G2/M phase, reducing the cells in G0/G1, 
confirming that BMP7v treatment is able to reduce CR-CSCs stemness trait.  
According to these data the treatment reduces CR-CSC motility and invasiveness, 
underlining the link between CSCs, epithelial-mesenchymal transition (EMT) and 
metastasis, as showed by the analysis of putative EMT markers: BMP7v 
suppressed the mesenchymal trait, inducing E-cadherin expression and 
cytoplasmic localization of beta-catenin, reducing Vimentin expression. 
To confirm the correlation between BMP and Wnt pathways suggested by western 
blotting analysis a Wnt signaling trascriptional profile was performed on CR-
CSCs after 48 hours of BMP7v treatment: BMP7v induced up-regulation of Wnt 
inhibitors such as SFRP2 and Axin2, associated with down regulation of stem cell 
markers, such as SOX2 e Nanog. In addition, the treatment reduced expression of 
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migration regulator genes, such as Met and MMP2 and 7. These results confirm 
the induction of differentiation via the Wnt pathway. 
The clinical results obtained in leukemia, sustain the combination of a pro-
differentiation agent with chemotherapy, suggesting the synergic action of 
BMP7v in combination with conventional drugs used in the management of CRC 
disease. BMP7v in combination with standard chemotherapy reduced CR-CSCs 
tumor growth in vivo as showed by strong reduction of tumor size, and by lower 
expression of CD133, CD166, beta-catenin, Lgr5 and Ki67, with a significant 
increase of CK20 compared to control, suggesting anti-proliferative and pro-
differentiative effects in vivo. 
Our findings confirm the rationale for combining a pro-differentiation agent with 
chemotherapy drugs, supporting the use of BMP7v in colorectal cancer patients. 
Since BMP7v treatment resulted in a notable necrotic effect, paraffin embedded 
xenografts sections were analyzed for CD31 and VEGFR2 expression. 
The histological examination showed a significant reduction of human CD31 and 
VEGFR2 expression following BMP7v treatment, but not BMP4 treatment. This 
anti-angiogenetic effect was confirmed through an endothelial tube formation 
assay. These findings confirm a specific anti-angiogenic effect of BMP7v in 
colorectal cancer xenografts 
BMP7v also showed a significant anti-tumor activity in xenografts refractory to 
chemotherapy, revealing a strong necrotic effect and a greater efficacy compared 
to combined treatment in tumor xenografts previously treated with standard 
chemotherapy. 
These results also support the possible use of BMP7v in colorectal cancer, 
providing evidence for its efficacy also in pre-treated patients.  
Concluding, the clinical benefit obtained by the combination of a 
prodifferentiative agent with chemotherapy led us to propose the combination of 
BMP7v with current standard chemotherapy regimens for CRC further supporting 
the usefulness of CSCs differentiation as a CRC therapy. 
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